View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2018	Jul. 31, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q2
Trading Symbol	ACHC
Entity Registrant Name	Acadia Healthcare Company, Inc.
Entity Central Index Key	0001520697
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		88,274,373

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 79,463	$ 67,290
Accounts receivable, net	329,256	296,925
Other current assets	80,503	107,335
Total current assets	489,222	471,550
Property and equipment, net	3,103,331	3,048,130
Goodwill	2,739,303	2,751,174
Intangible assets, net	91,566	87,348
Deferred tax assets	3,664	3,731
Derivative instrument assets	24,989	12,997
Other assets	51,072	49,572
Total assets	6,503,147	6,424,502
Current liabilities:
Current portion of long-term debt	33,264	34,830
Accounts payable	130,228	102,299
Accrued salaries and benefits	102,840	99,047
Other accrued liabilities	127,786	141,213
Total current liabilities	394,118	377,389
Long-term debt	3,187,788	3,205,058
Deferred tax liabilities	78,340	80,333
Other liabilities	160,809	166,434
Total liabilities	3,821,055	3,829,214
Redeemable noncontrolling interests	28,791	22,417
Equity:
Preferred stock, $0.01 par value; 10,000,000 shares authorized, no shares issued
Common stock, $0.01 par value; 180,000,000 shares authorized; 87,330,276 and 87,060,114 issued and outstanding at June 30, 2018 and December 31, 2017, respectively	873	871
Additional paid-in capital	2,530,083	2,517,545
Accumulated other comprehensive loss	(415,883)	(374,118)
Retained earnings	538,228	428,573
Total equity	2,653,301	2,572,871
Total liabilities and equity	$ 6,503,147	$ 6,424,502

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2018	Dec. 31, 2017
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, authorized	10,000,000	10,000,000
Preferred stock, issued	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	180,000,000	180,000,000
Common stock, shares issued	87,330,276	87,060,114
Common stock, shares outstanding	87,330,276	87,060,114

Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Income Statement [Abstract]
Revenue before provision for doubtful accounts	$ 765,738	$ 725,643	$ 1,507,979	$ 1,414,984
Provision for doubtful accounts		(9,747)		(19,894)
Revenue	765,738	715,896	1,507,979	1,395,090
Salaries, wages and benefits (including equity-based compensation expense of $7,129, $7,436, $14,048 and $14,832, respectively)	416,741	383,595	828,269	760,016
Professional fees	53,461	46,321	107,479	89,730
Supplies	30,133	28,639	59,497	56,348
Rents and leases	20,236	19,435	40,524	38,406
Other operating expenses	87,282	83,122	175,513	166,833
Depreciation and amortization	39,928	35,201	79,701	68,814
Interest expense, net	45,812	43,505	91,055	86,262
Debt extinguishment costs		810	940	810
Transaction-related expenses	2,887	9,052	7,655	13,171
Total expenses	696,480	649,680	1,390,633	1,280,390
Income before income taxes	69,258	66,216	117,346	114,700
Provision for income taxes	10,368	16,578	7,582	30,289
Net income	58,890	49,638	109,764	84,411
Net (income) loss attributable to noncontrolling interests	(54)	(8)	(109)	177
Net income attributable to Acadia Healthcare Company, Inc.	$ 58,836	$ 49,630	$ 109,655	$ 84,588
Earnings per share attributable to Acadia Healthcare Company, Inc. stockholders:
Basic	$ 0.67	$ 0.57	$ 1.26	$ 0.97
Diluted	$ 0.67	$ 0.57	$ 1.26	$ 0.97
Weighted-average shares outstanding:
Basic	87,303	86,954	87,205	86,859
Diluted	87,467	87,080	87,351	86,997

Condensed Consolidated Statements of Income (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Income Statement [Abstract]
Equity-based compensation expense	$ 7,129	$ 7,436	$ 14,048	$ 14,832

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Statement Of Income And Comprehensive Income [Abstract]
Net income	$ 58,890	$ 49,638	$ 109,764	$ 84,411
Other comprehensive (loss) income:
Foreign currency translation (loss) gain	(143,599)	92,076	(50,819)	119,122
Gain (loss) on derivative instruments, net of tax of $10.5 million, $(6.5) million, $3.2 million and $(12.1) million, respectively	29,107	(9,084)	9,054	(14,952)
Other comprehensive (loss) income	(114,492)	82,992	(41,765)	104,170
Comprehensive (loss) income	(55,602)	132,630	67,999	188,581
Comprehensive (gain) loss attributable to noncontrolling interests	(54)	(8)	(109)	177
Comprehensive (loss) income attributable to Acadia Healthcare Company, Inc.	$ (55,656)	$ 132,622	$ 67,890	$ 188,758

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=84234705&loc=SL4591551-111686

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3000-108585

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=84234705&loc=SL4591552-111686

+ Details

Condensed Consolidated Statements of Comprehensive Income (Unaudited) (Parenthetical) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Statement Of Income And Comprehensive Income [Abstract]
Loss on derivative instruments, tax	$ 10.5	$ (6.5)	$ 3.2	$ (12.1)

Condensed Consolidated Statement of Equity (Unaudited) - 6 months ended Jun. 30, 2018 - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Other Comprehensive Loss [Member]	Earnings (Accumulated Deficit) [Member]
Balance at Dec. 31, 2017	$ 2,572,871	$ 871	$ 2,517,545	$ (374,118)	$ 428,573
Balance, shares at Dec. 31, 2017	87,060,114	87,060
Common stock issued under stock incentive plans	$ 224	$ 2	222
Common stock issued under stock incentive plans, shares	8,689	270
Common stock withheld for minimum statutory taxes	$ (2,358)		(2,358)
Equity-based compensation expense	14,048		14,048
Other comprehensive loss	(41,765)			(41,765)
Other	626		626
Net income attributable to Acadia Healthcare Company, Inc.	109,655				109,655
Balance at Jun. 30, 2018	$ 2,653,301	$ 873	$ 2,530,083	$ (415,883)	$ 538,228
Balance, shares at Jun. 30, 2018	87,330,276	87,330

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Operating activities:
Net income	$ 109,764	$ 84,411
Adjustments to reconcile net income to net cash provided by continuing operating activities:
Depreciation and amortization	79,701	68,814
Amortization of debt issuance costs	5,124	4,845
Equity-based compensation expense	14,048	14,832
Deferred income taxes	(3,978)	17,096
Debt extinguishment costs	940	810
Other	1,040	6,558
Change in operating assets and liabilities:
Accounts receivable, net	(26,104)	(22,404)
Other current assets	9,953	20,457
Other assets	2,761	1,809
Accounts payable and other accrued liabilities	21,066	(4,893)
Accrued salaries and benefits	4,364	(9,157)
Other liabilities	(793)	5,257
Net cash provided by continuing operating activities	217,886	188,435
Net cash used in discontinued operating activities	(572)	(829)
Net cash provided by operating activities	217,314	187,606
Investing activities:
Cash paid for capital expenditures	(161,555)	(117,521)
Cash paid for real estate acquisitions	(8,857)	(22,850)
Other	(3,337)	(5,938)
Net cash used in investing activities	(173,749)	(146,309)
Financing activities:
Principal payments on long-term debt	(23,246)	(17,275)
Common stock withheld for minimum statutory taxes, net	(2,134)	(3,678)
Other	(5,172)	(2,270)
Net cash used in financing activities	(30,552)	(23,223)
Effect of exchange rate changes on cash	(840)	4,297
Net increase in cash and cash equivalents	12,173	22,371
Cash and cash equivalents at beginning of the period	67,290	57,063
Cash and cash equivalents at end of the period	$ 79,463	$ 79,434

Description of Business and Basis of Presentation

6 Months Ended

Jun. 30, 2018

Accounting Policies [Abstract]

Description of Business and Basis of Presentation

1.	Description of Business and Basis of Presentation

Description of Business

Acadia Healthcare Company, Inc. (the “Company”) develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities and facilities providing outpatient behavioral healthcare services to serve the behavioral health and recovery needs of communities throughout the United States (“U.S.”), the United Kingdom (“U.K.”) and Puerto Rico. At June 30, 2018, the Company operated 585 behavioral healthcare facilities with approximately 17,900 beds in 40 states, the U.K. and Puerto Rico.

Basis of Presentation

The business of the Company is conducted through limited liability companies, partnerships and C-corporations. The Company’s consolidated financial statements include the accounts of the Company and all subsidiaries controlled by the Company through its’ direct or indirect ownership of majority interests and exclusive rights granted to the Company as the controlling member of an entity. All intercompany accounts and transactions have been eliminated in consolidation.

The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for fair presentation of our financial position and results of operations have been included. The Company’s fiscal year ends on December 31 and interim results are not necessarily indicative of results for a full year or any other interim period. The condensed consolidated balance sheet at December 31, 2017 has been derived from the audited financial statements as of that date. The information contained in these condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements and notes thereto for the fiscal year ended December 31, 2017 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on February 27, 2018. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.

Certain reclassifications have been made to prior years to conform to the current year presentation.

Recently Issued Accounting Standards

6 Months Ended

Jun. 30, 2018

Accounting Changes And Error Corrections [Abstract]

Recently Issued Accounting Standards

2.	Recently Issued Accounting Standards

In August 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-12, “Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities” (“ASU 2017-12”). ASU 2017-12 amends the hedge accounting model to enable entities to better portray the economics of their risk management activities in the financial statements and simplifies the application of hedge accounting in certain situations. ASU 2017-12 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. Early adoption is permitted. Management is evaluating the impact of ASU 2017-12 on the Company’s consolidated financial statements.

In January 2017, the FASB issued ASU 2017-04, “Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment” (“ASU 2017-04”). ASU 2017-04 simplifies the measurement of goodwill by eliminating the requirement to calculate the implied fair value of goodwill (step 2 of the current impairment test) to measure the goodwill impairment charge. Instead, entities will record impairment charges based on the excess of a reporting unit’s carrying amount over its fair value. ASU 2017-04 is effective for fiscal years beginning after December 15, 2019. Early adoption is permitted. The Company has elected to early adopt ASU 2017-04 on January 1, 2018, and there was no significant impact on the Company’s consolidated financial statements.

In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments” (“ASU 2016-15”). ASU 2016-15 addresses treatment of how certain cash receipts and cash payments are presented and classified in the statement of cash flows to reduce the diversity in practice. ASU 2016-15 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. The Company adopted ASU 2016-15 on January 1, 2018. There is no significant impact on the Company’s consolidated financial statements.

In March 2016, the FASB issued ASU 2016-02, “Leases” (“ASU 2016-02”). ASU 2016-02’s core principle is to increase transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information. ASU 2016-02 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. Additionally, ASU 2016-02 would permit both public and nonpublic organizations to adopt the new standard early. Management believes the primary effect of adopting the new standard will be to record right-of-use assets and obligations for current operating leases. Management is currently evaluating the impact ASU 2016-02 will have on the Company’s consolidated financial statements, internal controls, policies and procedures.

In January 2016, the FASB issued ASU 2016-01, “Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities” (“ASU 2016-01”). ASU 2016-01 amends how entities recognize, measure, present and disclose certain financial assets and financial liabilities. It requires entities to measure equity investments (except for those accounted for under equity method) at fair value and recognize any changes in fair value in net income. ASU 2016-15 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. The Company adopted ASU 2016-01 on January 1, 2018. There was no significant impact on the Company’s consolidated financial statements.

In May 2014, the FASB and the International Accounting Standards Board issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)” (“ASU 2014-09”). ASU 2014-09’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASU 2014-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. The Company adopted ASU 2014-09 on January 1, 2018 as described in Note 3 – Revenue.

Revenue

6 Months Ended

Jun. 30, 2018

Revenue From Contract With Customer [Abstract]

Revenue

ASU 2014-09 requires companies to exercise more judgment and recognize revenue using a five-step process. The Company adopted ASU 2014-09 using the modified retrospective method for all contracts effective January 1, 2018 and is using a portfolio approach to group contracts with similar characteristics and analyze historical cash collections trends. Modified retrospective adoption requires entities to apply the standard retrospectively to the most current period presented in the financial statements, requiring the cumulative effect of the retrospective application as an adjustment to the opening balance of retained earnings at the date of initial application. Prior periods have not been adjusted. No cumulative-effect adjustment in retained earnings was recorded as the adoption of ASU 2014-09 did not significantly impact the Company’s reported historical revenue.

As a result of certain changes required by ASU 2014-09, the majority of the Company’s provision for doubtful accounts are recorded as a direct reduction to revenue instead of being presented as a separate line item on the condensed consolidated statements of income. The adoption of ASU 2014-09 has no impact on the Company’s accounts receivable as it was historically recorded net of allowance for doubtful accounts and contractual adjustments, and the Company has eliminated the presentation of allowance for doubtful accounts on the condensed consolidated balance sheets. The adoption of ASU 2014-09 did not have a significant impact on the Company’s condensed consolidated statements of income. The impact of adopting ASU 2014-09 on the condensed consolidated statements of income for the three and six months ended June 30, 2018 was as follows (in thousands):

	Three Months Ended June 30, 2018					Six Months Ended June 30, 2018
	As Reported		Prior to Adopting ASU 2014-09			As Reported		Prior to Adopting ASU 2014-09
Revenue before provision for doubtful accounts	$	765,738	$	775,203		$	1,507,979	$	1,525,704
Provision for doubtful accounts		—		(9,465	)		—		(17,725	)
Revenue	$	765,738	$	765,738		$	1,507,979	$	1,507,979

The Company evaluated the nature, amount, timing and uncertainty of revenue and cash flows using the five-step process provided within ASU 2014-09.

Revenue is primarily derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care and adolescent residential treatment. The services provided by the Company have no fixed duration and can be terminated by the patient or the facility at any time, and therefore, each treatment is its own stand-alone contract.

Services ordered by a healthcare provider in an episode of care are not separately identifiable and therefore have been combined into a single performance obligation for each contract. The Company recognizes revenue as its performance obligations are completed. The performance obligation is satisfied over time as the customer simultaneously receives and consumes the benefits of the healthcare services provided. For inpatient services, the Company recognizes revenue equally over the patient stay on a daily basis. For outpatient services, the Company recognizes revenue equally over the number of treatments provided in a single episode of care. Typically, patients and third-party payors are billed within several days of the service being performed or the patient being discharged, and payments are due based on contract terms.

As our performance obligations relate to contracts with a duration of one year or less, the Company elected the optional exemption in ASC 606-10-50-14(a). Therefore, the Company is not required to disclose the transaction price for the remaining performance obligations at the end of the reporting period or when the Company expects to recognize the revenue. The Company has minimal unsatisfied performance obligations at the end of the reporting period as our patients typically are under no obligation to remain admitted in our facilities.

The Company disaggregates revenue from contracts with customers by service type and by payor within each of the Company’s segments.

U.S. Facilities

The Company’s facilities in the United States (the “U.S. Facilities”) and services provided by the U.S. Facilities can generally be classified into the following categories: acute inpatient psychiatric facilities; specialty treatment facilities; residential treatment centers; and outpatient community-based services.

Acute inpatient psychiatric facilities. Acute inpatient psychiatric facilities provide a high level of care in order to stabilize patients that are either a threat to themselves or to others. The acute setting provides 24-hour observation, daily intervention and monitoring by psychiatrists.

Specialty treatment facilities. Specialty treatment facilities include residential recovery facilities, eating disorder facilities and comprehensive treatment centers. The Company provides a comprehensive continuum of care for adults with addictive disorders and co-occurring mental disorders. Inpatient, including detoxification and rehabilitation, partial hospitalization and outpatient treatment programs give patients access to the least restrictive level of care.

Residential treatment centers. Residential treatment centers treat patients with behavioral disorders in a non-hospital setting, including outdoor programs. The facilities balance therapy activities with social, academic and other activities.

Outpatient community-based services. Outpatient community-based programs are designed to provide therapeutic treatment to children and adolescents who have a clinically-defined emotional, psychiatric or chemical dependency disorder while enabling the youth to remain at home and within their community.

The table below presents total U.S. revenue attributed to each category (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
Acute inpatient psychiatric facilities	$	203,535	$	193,989	$	399,426	$	378,676
Specialty treatment facilities		192,894		182,748		377,429		357,945
Residential treatment centers		74,133		73,180		145,690		142,467
Outpatient community-based services		10,908		11,497		21,330		22,549
Revenue	$	481,470	$	461,414	$	943,875	$	901,637

The Company receives payments from the following sources for services rendered in our U.S. Facilities: (i) state governments under their respective Medicaid and other programs; (ii) commercial insurers; (iii) the federal government under the Medicare program administered by the Centers for Medicare and Medicaid Services (“CMS”); and (iv) individual patients and clients. As the period between the time of service and time of payment is typically one year or less, the Company elected the practical expedient under ASC 606-10-32-18 and did not adjust for the effects of a significant financing component.

The Company determines the transaction price based on established billing rates reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients and implicit price concessions. Contractual adjustments and discounts are based on contractual agreements, discount policies and historical experience. Implicit price concessions are based on historical collection experience. Most of our U.S. Facilities have contracts containing variable consideration. However, it is unlikely a significant reversal of revenue will occur when the uncertainty is resolved, and therefore, the Company has included the variable consideration in the estimated transaction price. Subsequent changes resulting from a patient’s ability to pay are recorded as bad debt expense, which is included as a component of other operating expenses in the condensed consolidating statements of income. Bad debt expense for the three and six months ended June 30, 2018 was not significant.

The Company derives a significant portion of its revenue from Medicare, Medicaid and other payors that receive discounts from established billing rates. The Medicare and Medicaid regulations and various managed care contracts under which these discounts must be calculated are complex, subject to interpretation and adjustment, and may include multiple reimbursement mechanisms for different types of services provided in the Company’s inpatient facilities and cost settlement provisions. Management estimates the transaction price on a payor-specific basis given its interpretation of the applicable regulations or contract terms. The services authorized and provided and related reimbursement are often subject to interpretation that could result in payments that differ from the Company’s estimates. Additionally, updated regulations and contract renegotiations occur frequently, necessitating regular review and assessment of the estimation process by management.

Settlements under cost reimbursement agreements with third-party payors are estimated and recorded in the period in which the related services are rendered and are adjusted in future periods as final settlements are determined. Final determination of amounts earned under the Medicare and Medicaid programs often occurs in subsequent years because of audits by such programs, rights of appeal and the application of numerous technical provisions. In the opinion of management, adequate provision has been made for any adjustments and final settlements. However, there can be no assurance that any such adjustments and final settlements will not have a material effect on the Company’s financial condition or results of operations. The Company’s cost report receivables were $12.2 million and $9.0 million at June 30, 2018 and December 31, 2017, respectively, and were included in other current assets in the condensed consolidated balance sheets. Management believes that these receivables are properly stated and are not likely to be settled for a significantly different amount. The net adjustments to estimated cost report settlements were not significant for the three and six months ended June 30, 2018.

Management believes that we comply in all material respects with applicable laws and regulations and is not aware of any material pending or threatened investigations involving allegations of wrongdoing. Compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action including fines, penalties and exclusion from the Medicare and Medicaid programs.

The Company provides care without charge to patients who are financially unable to pay for the healthcare services they receive based on Company policies and federal and state poverty thresholds. Such amounts determined to qualify as charity care are not reported as revenue. The cost of providing charity care services were $1.2 million and $1.4 million for the three months ended June 30, 2018 and 2017, respectively. The cost of providing charity care services were $2.8 million and $3.0 million for the six months ended June 30, 2018 and 2017, respectively. The estimated cost of charity care services was determined using a ratio of cost to gross charges determined from our most recently filed Medicare cost reports and applying that ratio to the gross charges associated with providing charity care for the period.

The following table presents revenue generated by each payor type (in thousands):

	Three Months Ended June 30,					Six Months Ended June 30,
	2018		2017			2018		2017
Commercial	$	147,279	$	149,493		$	284,898	$	288,948
Medicare		69,508		71,559			136,779		139,399
Medicaid		225,567		197,279			438,846		388,113
Self-Pay		33,379		43,561			70,286		87,243
Other		5,737		9,269			13,066		17,822
Revenue before provision for doubtful accounts		481,470		471,161			943,875		921,525
Provision for doubtful accounts		—		(9,747	)		—		(19,888	)
Revenue	$	481,470	$	461,414		$	943,875	$	901,637

U.K. Facilities

The Company’s facilities located in the United Kingdom (the “U.K. Facilities”) and services provided by the U.K. Facilities can generally be classified into the following categories: healthcare facilities, education and children’s services, adult care facilities and elderly care facilities.

Healthcare facilities. Healthcare facilities provide psychiatric treatment and nursing for sufferers of mental disorders, including for patients whose risk of harm to others and risk of escape from hospitals cannot be managed safely within other mental health settings. In order to manage the risks involved with treating patients, the facility is managed through the application of a range of security measures depending on the level of dependency and risk exhibited by the patient.

Education and children’s services. Education and children’s services provide specialist education for children and young people with special educational needs, including autism, Asperger’s Syndrome, social, emotional and mental health, and specific learning difficulties, such as dyslexia. The division also offers standalone children’s homes for children that require 52-week residential care to support complex and challenging behavior and fostering services.

Adult care facilities. Adult care focuses on care of individuals with a variety of learning difficulties, mental health illnesses and adult autism spectrum disorders. It also includes long-term, short-term and respite nursing care to high-dependency elderly individuals who are physically frail or suffering from dementia. Care is provided in a number of settings, including in residential care homes and through supported living.

The table below presents total U.K. revenue attributed to each category (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
Healthcare facilities	$	159,060	$	141,187	$	313,860	$	273,285
Education and Children’s Services		49,310		42,199		98,643		81,896
Adult Care facilities		75,898		71,096		151,601		138,272
Revenue	$	284,268	$	254,482	$	564,104	$	493,453

The Company receives payments from approximately 500 public funded sources in the U.K. (including the National Health Service (“NHS”), Clinical Commissioning Groups (“CCGs”) and local authorities in England, Scotland and Wales) and individual patients and clients. The Company determines the transaction price based on established billing rates by payor and is reduced by implicit price concessions. Implicit price concessions are insignificant in our U.K. Facilities. There is no significant variable consideration in our U.K. Facilities’ contracts. As the period between the time of service and time of payment is typically one year or less, the Company elected the practical expedient under ASC 606-10-32-18 and did not adjust for the effects of a significant financing component.

The following table presents revenue generated by each payor type (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
U.K. public funded sources	$	256,881	$	226,380	$	510,175	$	441,845
Self-Pay		27,272		23,889		52,340		46,090
Other		115		4,213		1,589		5,524
Revenue before provision for doubtful accounts		284,268		254,482		564,104		493,459
Provision for doubtful accounts		—		—		—		(6	)
Revenue	$	284,268	$	254,482	$	564,104	$	493,453

The Company’s contract liabilities primarily consist of unearned revenue in our U.K. Facilities and are included in other accrued liabilities on the condensed consolidated balance sheets. A summary of the activity in unearned revenue in the U.K. Facilities is as follows (in thousands):

Balance at December 31, 2017	$	30,812
Payments received		84,541
Revenue recognized		(82,580	)
Foreign currency translation loss		(1,340	)
Balance at June 30, 2018	$	31,433

Earnings Per Share

6 Months Ended

Jun. 30, 2018

Earnings Per Share [Abstract]

Earnings Per Share

4.	Earnings Per Share

The following table sets forth the computation of basic and diluted earnings per share for the three and six months ended June 30, 2018 and 2017 (in thousands, except per share amounts):

	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
Numerator:
Net income attributable to Acadia Healthcare Company, Inc.	$	58,836	$	49,630	$	109,655	$	84,588
Denominator:
Weighted average shares outstanding for basic earnings per share		87,303		86,954		87,205		86,859
Effect of dilutive instruments		164		126		146		138
Shares used in computing diluted earnings per common share		87,467		87,080		87,351		86,997
Earnings per share attributable to Acadia Healthcare Company, Inc. stockholders:
Basic	$	0.67	$	0.57	$	1.26	$	0.97
Diluted	$	0.67	$	0.57	$	1.26	$	0.97

Approximately 1.6 million shares of common stock issuable upon exercise of outstanding stock option awards were excluded from the calculation of diluted earnings per share for both the three months ended June 30, 2018 and 2017, respectively, because their effect would have been anti-dilutive. Approximately 2.0 million and 1.1 million shares of common stock issuable upon exercise of outstanding stock option awards were excluded from the calculation of diluted earnings per share for the six months ended June 30, 2018 and 2017, respectively, because their effect would have been anti-dilutive.

Other Intangible Assets

6 Months Ended

Jun. 30, 2018

Goodwill And Intangible Assets Disclosure [Abstract]

Other Intangible Assets

5.	Other Intangible Assets

Other identifiable intangible assets and related accumulated amortization consisted of the following at June 30, 2018 and December 31, 2017 (in thousands):

	Gross Carrying Amount				Accumulated Amortization
	June 30, 2018		December 31, 2017		June 30, 2018			December 31, 2017
Intangible assets subject to amortization:
Contract intangible assets	$	2,100	$	2,100	$	(2,100	)	$	(2,100	)
Non-compete agreements		1,147		1,147		(1,147	)		(1,147	)
		3,247		3,247		(3,247	)		(3,247	)
Intangible assets not subject to amortization:
Licenses and accreditations		12,772		12,266		—			—
Trade names		61,960		60,586		—			—
Certificates of need		16,834		14,496		—			—
		91,566		87,348		—			—
Total	$	94,813	$	90,595	$	(3,247	)	$	(3,247	)

All the Company’s defined-lived intangible assets are fully amortized. The Company’s licenses and accreditations, trade names and certificate of need intangible assets have indefinite lives and are, therefore, not subject to amortization.

Property and Equipment

6 Months Ended

Jun. 30, 2018

Property Plant And Equipment [Abstract]

Property and Equipment

6.	Property and Equipment

Property and equipment consists of the following at June 30, 2018 and December 31, 2017 (in thousands):

	June 30, 2018			December 31, 2017
Land	$	451,264		$	450,342
Building and improvements		2,440,139			2,370,918
Equipment		438,033			400,596
Construction in progress		195,697			173,693
		3,525,133			3,395,549
Less accumulated depreciation		(421,802	)		(347,419	)
Property and equipment, net	$	3,103,331		$	3,048,130

Long-Term Debt

6 Months Ended

Jun. 30, 2018

Debt Disclosure [Abstract]

Long-Term Debt

7.	Long-Term Debt

Long-term debt consisted of the following (in thousands):

	June 30, 2018			December 31, 2017
Amended and Restated Senior Credit Facility:
Senior Secured Term A Loans	$	375,250		$	380,000
Senior Secured Term B Loans		1,379,904			1,398,400
Senior Secured Revolving Line of Credit		—			—
6.125% Senior Notes due 2021		150,000			150,000
5.125% Senior Notes due 2022		300,000			300,000
5.625% Senior Notes due 2023		650,000			650,000
6.500% Senior Notes due 2024		390,000			390,000
9.0% and 9.5% Revenue Bonds		21,920			21,920
Less: unamortized debt issuance costs, discount and premium		(46,022	)		(50,432	)
		3,221,052			3,239,888
Less: current portion		(33,264	)		(34,830	)
Long-term debt	$	3,187,788		$	3,205,058

Amended and Restated Senior Credit Facility

The Company entered into a senior secured credit facility (the “Senior Secured Credit Facility”) on April 1, 2011. On December 31, 2012, the Company entered into an Amended and Restated Credit Agreement (the “Amended and Restated Credit Agreement”) which amended and restated the Senior Secured Credit Facility (the “Amended and Restated Senior Credit Facility”). The Company has amended the Amended and Restated Credit Agreement from time to time as described in the Company’s prior filings with the SEC.

On May 10, 2017, the Company entered into a Third Repricing Amendment (the “Third Repricing Amendment”) to the Amended and Restated Credit Agreement. The Third Repricing Amendment reduced the Applicable Rate with respect to the Term Loan B facility Tranche B-1 (the “Tranche B-1 Facility”) and the Term Loan B facility Tranche B-2 (the “Tranche B-2 Facility”) from 3.00% to 2.75% in the case of Eurodollar Rate loans and from 2.00% to 1.75% in the case of Base Rate Loans. In connection with the Third Repricing Amendment, the Company recorded a debt extinguishment charge of $0.8 million, including the discount and write-off of deferred financing costs, which was recorded in debt extinguishment costs in the condensed consolidated statements of income.

On March 22, 2018, the Company entered into a Second Repricing Facilities Amendment (the “Second Repricing Facilities Amendment”) to the Amended and Restated Credit Agreement. The Second Repricing Facilities Amendment (i) replaced the Tranche B-1 Facility and the Tranche B-2 Facility with a new Term Loan B facility Tranche B-3 (the “Tranche B-3 Facility”) and a new Term Loan B facility Tranche B-4 (the “Tranche B-4 Facility”), respectively, and (ii) reduced the Applicable Rate from 2.75% to 2.50% in the case of Eurodollar Rate loans and reduced the Applicable Rate from 1.75% to 1.50% in the case of Base Rate Loans.

On March 29, 2018, the Company entered into a Third Repricing Facilities Amendment to the Amended and Restated Credit Agreement (the “Third Repricing Facilities Amendment”, and together with the Second Repricing Facilities Amendment, the “Repricing Facilities Amendments”). The Third Repricing Facilities Amendment replaced the existing revolving credit facility and Term Loan A facility (“TLA Facility”) with a new revolving credit facility and TLA Facility, respectively. The Company’s line of credit on its revolving credit facility remains at $500.0 million and the Third Repricing Facility Amendment reduced the size of the TLA Facility from $400.0 million to $380.0 million to reflect the then current outstanding principal. The Third Repricing Facilities Amendment reduced the Applicable Rate by 25 basis points for the revolving credit facility and the TLA Facility by amending the definition of “Applicable Rate.”

In connection with the Repricing Facilities Amendments, the Company recorded a debt extinguishment charge of $0.9 million, including the discount and write-off of deferred financing costs, which was recorded in debt extinguishment costs in the condensed consolidated statements of income.

The Company had $495.0 million of availability under the revolving line of credit and had standby letters of credit outstanding of $5.0 million related to security for the payment of claims required by its workers’ compensation insurance program at June 30, 2018. Borrowings under the revolving line of credit are subject to customary conditions precedent to borrowing. The Amended and Restated Credit Agreement requires quarterly term loan principal repayments of our TLA Facility of $4.8 million for September 30, 2018 to December 31, 2019, $7.1 million for March 31, 2020 to December 31, 2020, and $9.5 million for March 31, 2021 to September 30, 2021, with the remaining principal balance of the TLA Facility due on the maturity date of November 30, 2021. The Company is required to repay the Tranche B-3 Facility in equal quarterly installments of $1.2 million on the last business day of each March, June, September and December, with the outstanding principal balance of the Tranche B-3 Facility due on February 11, 2022. The Company is required to repay the Tranche B-4 Facility in equal quarterly installments of approximately $2.3 million on the last business day of each March, June, September and December, with the outstanding principal balance of the Tranche B-4 Facility due on February 16, 2023. On December 29, 2017, the Company made an additional payment of $22.5 million, including $7.7 million on the Tranche B-1 Facility and $14.8 million on the Tranche B-2 Facility. On April 17, 2018, the Company made an additional payment of $15.0 million, including $5.1 million on the Tranche B-3 Facility and $9.9 million on the Tranche B-4 Facility.

Borrowings under the Amended and Restated Senior Credit Facility are guaranteed by each of the Company’s wholly-owned domestic subsidiaries (other than certain excluded subsidiaries) and are secured by a lien on substantially all of the assets of the Company and such subsidiaries. Borrowings with respect to the TLA Facility and the Company’s revolving credit facility (collectively, “Pro Rata Facilities”) under the Amended and Restated Credit Agreement bear interest at a rate tied to Acadia’s Consolidated Leverage Ratio (defined as consolidated funded debt net of up to $40.0 million of unrestricted and unencumbered cash to consolidated EBITDA, in each case as defined in the Amended and Restated Credit Agreement). The Applicable Rate (as defined in the Amended and Restated Credit Agreement) for the Pro Rata Facilities was 2.50% for Eurodollar Rate Loans (as defined in the Amended and Restated Credit Agreement) and 1.50% for Base Rate Loans (as defined in the Amended and Restated Credit Agreement) at June 30, 2018. Eurodollar Rate Loans with respect to the Pro Rata Facilities bear interest at the Applicable Rate plus the Eurodollar Rate (as defined in the Amended and Restated Credit Agreement) (based upon the LIBOR Rate (as defined in the Amended and Restated Credit Agreement) prior to commencement of the interest rate period). Base Rate Loans with respect to the Pro Rata Facilities bear interest at the Applicable Rate plus the highest of (i) the federal funds rate plus 0.50%, (ii) the prime rate and (iii) the Eurodollar Rate plus 1.00%. At June 30, 2018, the Pro Rata Facilities bore interest at a rate of LIBOR plus 2.50%. In addition, the Company is required to pay a commitment fee on undrawn amounts under the revolving line of credit.

The Amended and Restated Credit Agreement requires the Company and its subsidiaries to comply with customary affirmative, negative and financial covenants, including a fixed charge coverage ratio, consolidated leverage ratio and senior secured leverage ratio. The Company may be required to pay all of its indebtedness immediately if it defaults on any of the numerous financial or other restrictive covenants contained in any of its material debt agreements. At June 30, 2018, the Company was in compliance with such covenants.

Senior Notes

6.125% Senior Notes due 2021

On March 12, 2013, the Company issued $150.0 million of 6.125% Senior Notes due 2021 (the “6.125% Senior Notes”). The 6.125% Senior Notes mature on March 15, 2021 and bear interest at a rate of 6.125% per annum, payable semi-annually in arrears on March 15 and September 15 of each year.

5.125% Senior Notes due 2022

On July 1, 2014, the Company issued $300.0 million of 5.125% Senior Notes due 2022 (the “5.125% Senior Notes”). The 5.125% Senior Notes mature on July 1, 2022 and bear interest at a rate of 5.125% per annum, payable semi-annually in arrears on January 1 and July 1 of each year.

5.625% Senior Notes due 2023

On February 11, 2015, the Company issued $375.0 million of 5.625% Senior Notes due 2023 (the “5.625% Senior Notes”). On September 21, 2015, the Company issued $275.0 million of additional 5.625% Senior Notes. The additional notes formed a single class of debt securities with the 5.625% Senior Notes issued in February 2015. Giving effect to this issuance, the Company has outstanding an aggregate of $650.0 million of 5.625% Senior Notes. The 5.625% Senior Notes mature on February 15, 2023 and bear interest at a rate of 5.625% per annum, payable semi-annually in arrears on February 15 and August 15 of each year.

6.500% Senior Notes due 2024

On February 16, 2016, the Company issued $390.0 million of 6.500% Senior Notes due 2024 (the “6.500% Senior Notes”). The 6.500% Senior Notes mature on March 1, 2024 and bear interest at a rate of 6.500% per annum, payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2016.

The indentures governing the 6.125% Senior Notes, 5.125% Senior Notes, 5.625% Senior Notes and 6.500% Senior Notes (together, the “Senior Notes”) contain covenants that, among other things, limit the Company’s ability and the ability of its restricted subsidiaries to: (i) pay dividends, redeem stock or make other distributions or investments; (ii) incur additional debt or issue certain preferred stock; (iii) transfer or sell assets; (iv) engage in certain transactions with affiliates; (v) create restrictions on dividends or other payments by the restricted subsidiaries; (vi) merge, consolidate or sell substantially all of the Company’s assets; and (vii) create liens on assets.

The Senior Notes issued by the Company are guaranteed by each of the Company’s subsidiaries that guarantee the Company’s obligations under the Amended and Restated Senior Credit Facility. The guarantees are full and unconditional and joint and several.

The Company may redeem the Senior Notes at its option, in whole or part, at the dates and amounts set forth in the indentures.

9.0% and 9.5% Revenue Bonds

On November 11, 2012, in connection with the acquisition of The Pavilion at HealthPark, LLC (“Park Royal”), the Company assumed debt of $23.0 million. The fair market value of the debt assumed was $25.6 million and resulted in a debt premium balance being recorded as of the acquisition date. The debt consisted of $7.5 million and $15.5 million of Lee County (Florida) Industrial Development Authority Healthcare Facilities Revenue Bonds, Series 2010 with stated interest rates of 9.0% and 9.5% (“9.0% and 9.5% Revenue Bonds”), respectively. The 9.0% bonds in the amount of $7.5 million have a maturity date of December 1, 2030 and require yearly principal payments beginning in 2013. The 9.5% bonds in the amount of $15.5 million have a maturity date of December 1, 2040 and require yearly principal payments beginning in 2031. The principal payments establish a bond sinking fund to be held with the trustee and shall be sufficient to redeem the principal amounts of the 9.0% and 9.5% Revenue Bonds on their respective maturity dates. At June 30, 2018 and December 31, 2017, $2.3 million was recorded within other assets on the condensed consolidated balance sheets related to the debt service reserve fund requirements. The yearly principal payments, which establish a bond sinking fund, will increase the debt service reserve fund requirements. The bond premium amount of $2.6 million is amortized as a reduction of interest expense over the life of the revenue bonds using the effective interest method.

Equity-Based Compensation

6 Months Ended

Jun. 30, 2018

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Equity-Based Compensation

8	Equity-Based Compensation

Equity Incentive Plans

The Company issues stock-based awards, including stock options, restricted stock and restricted stock units, to certain officers, employees and non-employee directors under the Acadia Healthcare Company, Inc. Incentive Compensation Plan (the “Equity Incentive Plan”). At June 30, 2018, a maximum of 8,200,000 shares of the Company’s common stock were authorized for issuance as stock options, restricted stock and restricted stock units or other share-based compensation under the Equity Incentive Plan, of which 3,221,669 were available for future grant. Stock options may be granted for terms of up to ten years. The Company recognizes expense on all share-based awards on a straight-line basis over the requisite service period of the entire award. Grants to employees generally vest in annual increments of 25% each year, commencing one year after the date of grant. The exercise prices of stock options are equal to the most recent closing price of the Company’s common stock on the date of grant.

The Company recognized $7.1 million and $7.4 million in equity-based compensation expense for the three months ended June 30, 2018 and 2017, respectively, and $14.0 million and $14.8 million for the six months ended June 30, 2018 and 2017. At June 30, 2018, there was $56.5 million of unrecognized compensation expense related to unvested options, restricted stock and restricted stock units, which is expected to be recognized over the remaining weighted average vesting period of 1.3 years.

At June 30, 2018, there were no warrants outstanding. The Company recognized a deferred income tax benefit of $1.9 million and $2.8 million for the three months ended June 30, 2018 and 2017, respectively, related to equity-based compensation expense. The Company recognized a deferred income tax benefit of $3.8 million and $5.7 million for the six months ended June 30, 2018 and 2017, respectively, related to equity-based compensation expense.

Stock Options

Stock option activity during 2017 and 2018 was as follows (aggregate intrinsic value in thousands):

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Options outstanding at January 1, 2017		1,000,946		$	49.42		7.80	$	8,166
Options granted		259,300			42.25		9.30		205
Options exercised		(87,367	)		25.92	N/A			1,636
Options cancelled		(198,313	)		54.71	N/A		N/A
Options outstanding at December 31, 2017		974,566			47.89		7.46		3,802
Options granted		353,800			37.36		7.85		137
Options exercised		(8,689	)		25.87	N/A			134
Options cancelled		(86,112	)		51.97	N/A		N/A
Options outstanding at June 30, 2018		1,233,565		$	44.70		7.42	$	2,764
Options exercisable at December 31, 2017		405,634		$	41.20		6.05	$	3,549
Options exercisable at June 30, 2018		541,589		$	44.53		6.11	$	2,494

Fair values are estimated using the Black-Scholes option pricing model. The following table summarizes the grant-date fair value of options and the assumptions used to develop the fair value estimates for options granted during the six months ended June 30, 2018 and year ended December 31, 2017:

	June 30, 2018			December 31, 2017
Weighted average grant-date fair value of options	$	13.61		$	14.39
Risk-free interest rate		2.2	%		2.0	%
Expected volatility		38	%		33	%
Expected life (in years)		5.0			5.5

The Company’s estimate of expected volatility for stock options is based upon the volatility of our stock price over the expected life of the award. The risk-free interest rate is the approximate yield on U. S. Treasury Strips having a life equal to the expected option life on the date of grant. The expected life is an estimate of the number of years an option will be held before it is exercised.

Other Stock-Based Awards

Restricted stock activity during 2017 and 2018 was as follows:

	Number of Shares			Weighted Average Grant-Date Fair Value
Unvested at January 1, 2017		844,419		$	55.76
Granted		404,224			42.38
Cancelled		(145,981	)		55.03
Vested		(292,794	)		53.07
Unvested at December 31, 2017		809,868		$	50.19
Granted		441,837			36.51
Cancelled		(58,217	)		49.25
Vested		(245,814	)		53.44
Unvested at June 30, 2018		947,674		$	43.03

Restricted stock unit activity during 2017 and 2018 was as follows:

	Number of Units			Weighted Average Grant-Date Fair Value
Unvested at January 1, 2017		273,599		$	59.68
Granted		219,840			43.23
Cancelled		—			—
Vested		(132,530	)		58.67
Unvested at December 31, 2017		360,909		$	50.04
Granted		285,358			42.26
Cancelled		(89,173	)		55.44
Vested		(72,983	)		49.64
Unvested at June 30, 2018		484,111		$	44.52

Restricted stock awards are time-based vesting awards that vest over a period of three or four years and are subject to continuing service of the employee or non-employee director over the ratable vesting periods. The fair values of the restricted stock awards were determined based on the closing price of the Company’s common stock on the trading date immediately prior to the grant date.

Restricted stock units are granted to employees and are subject to Company performance compared to pre-established targets and, in the case of the 2018 awards, Company performance compared to peers. In addition to Company performance, these performance-based restricted stock units are subject to the continuing service of the employee during the two- or three-year period covered by the awards. The performance condition for the restricted stock units is based on the Company’s achievement of annually established targets for diluted earnings per share. Additionally, the number of shares issuable pursuant to restricted stock units granted during 2018 is subject to adjustment based on the Company’s three-year annualized total stockholder return relative to a peer group consisting of S&P 1500 companies within the Healthcare Providers & Services 6 digit GICS industry group and selected other companies deemed to be peers. The number of shares issuable at the end of the applicable vesting period of restricted stock units ranges from 0% to 200% of the targeted units based on the Company’s actual performance compared to the targets and, for 2018 awards, performance compared to peers.

The fair values of restricted stock units were determined based on the closing price of the Company’s common stock on the trading date immediately prior to the grant date for units subject to performance conditions, or at its Monte-Carlo simulation value for units subject to market conditions.

Income Taxes

6 Months Ended

Jun. 30, 2018

Income Tax Disclosure [Abstract]

Income Taxes

9.	Income Taxes

The provision for income taxes for the three months ended June 30, 2018 and 2017 reflects effective tax rates of 15.0% and 25.0%, respectively. The provision for income taxes for the six months ended June 30, 2018 and 2017 reflects effective tax rates of 6.5% and 26.4%, respectively. The decrease in the effective tax rate for the three and six months ended June 30, 2018 and 2017 was primarily attributable to the application of Public Law 115-97, informally referred to as the Tax Cuts and Jobs Act (the “Tax Act”) and a discrete benefit of $10.5 million recorded in the six months ended June 30, 2018 related to a change in the Company’s provisional amount recorded at December 31, 2017.

The Company adopted ASU 2016-09, “Improvements to Employee Share-Based Payment Accounting” on January 1, 2017, which changed how the Company accounts for share-based awards for tax purposes. Income tax effects of share-based awards are recognized in the income statement, instead of through equity, when the awards vest. These changes resulted in an increase in our income tax provision of $1.6 million and $1.7 million, or an increase in the effective tax rate of 1.4% and 1.5% for the six months ended June 30, 2018 and 2017, respectively.

U.S. Tax Reform

On December 22, 2017, the Tax Act was enacted into law. The Tax Act provides for significant changes to the U.S. tax code that impact businesses. Effective January 1, 2018, the Tax Act reduces the U.S. federal tax rate for corporations from 35% to 21%, for U.S. taxable income. The Tax Act requires a one-time remeasurement of deferred taxes to reflect their value at a lower tax rate of 21%. The Tax Act includes other changes, including, but not limited to, requiring a one-time transition tax on certain repatriated earnings of foreign subsidiaries that is payable over eight years, a general elimination of U.S. federal income taxes on dividends from foreign subsidiaries, a new provision designed to tax global intangible low-taxed income, a limitation of the deduction for net operating losses, elimination of net operating loss carrybacks, immediate deductions for depreciation expense for certain qualified property, additional limitations on the deductibility of executive compensation and limitations on the deductibility of interest.

Accounting Standards Codification (“ASC”) 740 “Income Taxes” (“ASC 740”) requires the Company to recognize the effect of tax law changes in the period of enactment. However, the SEC staff issued Staff Accounting Bulletin 118 (“SAB 118”) which will allow the Company to record provisional amounts during a measurement period similarly to the measurement period used when accounting for business combinations. The Company will continue to assess the impact of the Tax Act on its business and consolidated financial statements.

At June 30, 2018, the Company had not completed its accounting for the tax effects of enactment of the Tax Act; however, in certain cases, as described below, the Company has made a reasonable estimate of the effects on its existing deferred tax balances. The Company has recognized a cumulative provisional amount of $19.3 million at June 30, 2018 related to the remeasurement of its deferred tax balance. In addition, the Company has recorded a one-time transition tax lability in relation to its foreign subsidiaries of $0.0 million at June 30, 2018. The amount may change when the calculation of post-1986 foreign earnings and profits previously deferred from U.S. federal taxation is finalized.

Provisional Amounts

Deferred Tax Assets and Liabilities

The Company remeasured certain deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future, which is generally 21%. As a result of the reduction in the corporate income tax rate, the Company is required to revalue its net deferred tax assets and liabilities to account for the future impact of lower corporate tax rates on this deferred amount and record any change in the value of such asset or liability as a one-time non-cash charge or benefit on its income statement. However, the Company is still analyzing certain aspects of the Tax Act, which could potentially affect the measurement of these balances or potentially give rise to new deferred tax amounts. The Company has recognized a cumulative provisional amount of $19.3 million at June 30, 2018 related to the remeasurement of its deferred tax balance.

U.S. Tax on Foreign Earnings

The one-time transition tax is based on total post-1986 earnings and profits that the Company previously deferred from U.S. income taxes. The Company has made sufficient progress on the earnings and profits analysis for its foreign subsidiaries to reasonably estimate the effects of the one-time transition tax and has recorded a provisional amount of $0.0 million at June 30, 2018. This amount may change when the Company finalizes the calculation of post-1986 foreign earnings and profit. As part of the analysis of the Tax Act, the Company made an adjustment regarding the treatment of foreign dividends of $10.9 million during the six months ended June 30, 2018. The change in the provisional estimate recorded at December 31, 2017 was recognized under the law that existed prior to December 22, 2017.

The Company has estimated the impacts for Global Intangible Low-Taxed Income, Foreign-Derived Intangible Income, the Base Erosion and Anti-Abuse Tax and any remaining impacts of the foreign income provisions of the Tax Act. The Company has made sufficient progress to reasonably estimate the effects of the aforementioned items and has recorded a provisional amount of $0.0 million at June 30, 2018.

Derivatives

6 Months Ended

Jun. 30, 2018

Derivative Instruments And Hedging Activities Disclosure [Abstract]

Derivatives

10.	Derivatives

The Company entered into foreign currency forward contracts during the three and six months ended June 30, 2018 and 2017 in connection with certain transfers of cash between the U.S. and U.K. under the Company’s cash management and foreign currency risk management programs. Foreign currency forward contracts limit the economic risk of changes in the exchange rate between U.S. Dollars (“USD”) and British Pounds (“GBP”) associated with cash transfers.

In May 2016, the Company entered into multiple cross currency swap agreements with an aggregate notional amount of $650.0 million to manage foreign currency risk by effectively converting a portion of its fixed-rate USD-denominated senior notes, including the semi-annual interest payments thereunder, to fixed-rate GBP-denominated debt of £449.3 million. During the term of the swap agreements, the Company will receive semi-annual interest payments in USD from the counterparties at fixed interest rates, and the Company will make semi-annual interest payments in GBP to the counterparties at fixed interest rates. The interest payments under the cross-currency swap agreements result in £24.7 million of annual cash flows, from the Company’s U.K. business being converted to $35.8 million (at a 1.45 exchange rate).

The Company has designated the cross currency swap agreements and forward contracts entered into during 2017 and the six months ended June 30, 2018 as qualifying hedging instruments and is accounting for these as net investment hedges. The fair value of these derivatives of $25.0 million is recorded as derivative instrument assets on the condensed consolidated balance sheets. The gains and losses resulting from fair value adjustments to the cross currency swap agreements are recorded in accumulated other comprehensive loss as the swaps are effective in hedging the designated risk. Cash flows related to the cross currency swap derivatives are included in operating activities in the condensed consolidated statements of cash flows.

Fair Value Measurements

6 Months Ended

Jun. 30, 2018

Fair Value Disclosures [Abstract]

Fair Value Measurements

11.	Fair Value Measurements

The carrying amounts reported for cash and cash equivalents, accounts receivable, other current assets, accounts payable and other current liabilities approximate fair value because of the short-term maturity of these instruments.

The carrying amounts and fair values of the Company’s Amended and Restated Senior Credit Facility, 6.125% Senior Notes, 5.125% Senior Notes, 5.625% Senior Notes, 6.500% Senior Notes, 9.0% and 9.5% Revenue Bonds and derivative instruments at June 30, 2018 and December 31, 2017 were as follows (in thousands):

	Carrying Amount				Fair Value
	June 30, 2018		December 31, 2017		June 30, 2018		December 31, 2017
Amended and Restated Senior Credit Facility	$	1,728,688	$	1,749,185	$	1,728,688	$	1,749,185
6.125% Senior Notes due 2021	$	148,373	$	148,098	$	149,857	$	150,134
5.125% Senior Notes due 2022	$	296,555	$	296,174	$	295,814	$	296,914
5.625% Senior Notes due 2023	$	642,580	$	641,891	$	647,399	$	651,519
6.500% Senior Notes due 2024	$	382,769	$	382,251	$	392,338	$	397,541
9.0% and 9.5% Revenue Bonds	$	22,087	$	22,289	$	22,087	$	22,289
Derivative instrument assets	$	24,989	$	12,997	$	24,989	$	12,997

The Company’s Amended and Restated Senior Credit Facility, 6.125% Senior Notes, 5.125% Senior Notes, 5.625% Senior Notes, 6.500% Senior Notes and 9.0% and 9.5% Revenue Bonds were categorized as Level 2 in the GAAP fair value hierarchy. Fair values were based on trading activity among the Company’s lenders and the average bid and ask price as determined using published rates.

The fair values of the derivative instruments were categorized as Level 2 in the GAAP fair value hierarchy and were based on observable market inputs including applicable exchange rates and interest rates.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Commitments and Contingencies

6 Months Ended

Jun. 30, 2018

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

12.	Commitments and Contingencies

Professional and General Liability

A portion of the Company’s professional liability risks are insured through a wholly-owned insurance subsidiary. The Company is self-insured for professional liability claims up to $3.0 million per claim and has obtained reinsurance coverage from a third party to cover claims in excess of the retention limit. The reinsurance policy has a coverage limit of $75.0 million in the aggregate. The Company’s reinsurance receivables are recognized consistent with the related liabilities and include known claims and any incurred but not reported claims that are covered by current insurance policies in place.

Legal Proceedings

The Company is, from time to time, subject to various claims, governmental investigations and regulatory actions, including claims for damages for personal injuries, medical malpractice, overpayments, breach of contract, securities law violations, tort and employment related claims. In these actions, plaintiffs request a variety of damages, including, in some instances, punitive and other types of damages that may not be covered by insurance. In addition, healthcare companies are subject to numerous investigations by various governmental agencies. Under the federal False Claims Act, private parties have the right to bring qui tam, or “whistleblower,” suits against companies that submit false claims for payments to, or improperly retain overpayments from, the government. Some states have adopted similar state whistleblower and false claims provisions. Certain of our individual facilities have received, and from time to time, other facilities may receive, government inquiries from, and may be subject to investigation by, federal and state agencies. In the opinion of management, the Company is not currently a party to any proceeding that would individually or in the aggregate have a material adverse effect on the Company’s business, financial condition or results of operations.

Noncontrolling Interests

6 Months Ended

Jun. 30, 2018

Noncontrolling Interest [Abstract]

Noncontrolling Interests

13.	Noncontrolling Interests

Noncontrolling interests in the consolidated financial statements represents the portion of equity held by noncontrolling partners in non-wholly owned subsidiaries the Company controls. At June 30, 2018, certain of these non-wholly owned subsidiaries operated four facilities. The Company owns between 60% and 80% of the equity interests in the entity that owns each facility, and noncontrolling partners own the remaining equity interests. The initial value of the noncontrolling interests is based on the fair value of contributions, and the Company consolidates the operations of each facility based on its equity ownership and its control of the entity. The noncontrolling interests are reflected as redeemable noncontrolling interests on the condensed consolidated balance sheets based on put rights that could require the Company to purchase the noncontrolling interests upon the occurrence of a change in control.

The components of redeemable noncontrolling interests are as follows (in thousands):

Balance at December 31, 2017	$	22,417
Contribution of redeemable noncontrolling interests		6,265
Net income attributable to noncontrolling interests		109
Balance at June 30, 2018	$	28,791

Other Current Assets

6 Months Ended

Jun. 30, 2018

Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]

Other Current Assets

14.	Other Current Assets

Other current assets consisted of the following (in thousands):

	June 30, 2018		December 31, 2017
Prepaid expenses	$	28,379	$	27,320
Other receivables		29,791		30,455
Workers’ compensation deposits – current portion		10,000		10,000
Inventory		4,733		4,787
Income taxes receivable		3,885		15,056
Insurance receivable-current portion		1,688		17,588
Other		2,027		2,129
Other current assets	$	80,503	$	107,335

Other Accrued Liabilities

6 Months Ended

Jun. 30, 2018

Other Liabilities Disclosure [Abstract]

Other Accrued Liabilities

15.	Other Accrued Liabilities

Other accrued liabilities consisted of the following (in thousands):

	June 30, 2018		December 31, 2017
Accrued interest	$	33,156	$	36,370
Unearned income		32,362		31,342
Accrued expenses		32,113		37,268
Income taxes payable		8,966		1,012
Insurance liability – current portion		6,888		22,788
Accrued property taxes		4,530		3,945
Other		9,771		8,488
Other accrued liabilities	$	127,786	$	141,213

Segment Information

6 Months Ended

Jun. 30, 2018

Segment Reporting [Abstract]

Segment Information

16.	Segment Information

The Company operates in one line of business, which is operating acute inpatient psychiatric facilities, specialty treatment facilities, residential treatment centers and facilities providing outpatient behavioral healthcare services. As management reviews the operating results of its facilities in the U.S. and its facilities in the U.K. separately to assess performance and make decisions, the Company’s operating segments include our U.S. Facilities and U.K. Facilities. At June 30, 2018, the U.S. Facilities segment included 213 behavioral healthcare facilities with approximately 9,100 beds in 40 states and Puerto Rico, and the U.K. Facilities segment included 372 behavioral healthcare facilities with approximately 8,800 beds in the U.K.

The following tables set forth the financial information by operating segment, including a reconciliation of Segment EBITDA to income before income taxes (in thousands):

	Three Months Ended June 30,						Six Months Ended June 30,
	2018			2017			2018			2017
Revenue:
U.S. Facilities	$	481,470		$	461,414		$	943,875		$	901,637
U.K. Facilities		284,268			254,482			564,104			493,453
Corporate and Other		—			—			—			—
	$	765,738		$	715,896		$	1,507,979		$	1,395,090
Segment EBITDA (1):
U.S. Facilities	$	130,002		$	128,361		$	247,126		$	240,506
U.K. Facilities		54,194			52,090			105,346			96,276
Corporate and Other		(19,182	)		(18,231	)		(41,727	)		(38,193	)
	$	165,014		$	162,220		$	310,745		$	298,589

	Three Months Ended June 30,						Six Months Ended June 30,
	2018			2017			2018			2017
Segment EBITDA (1)	$	165,014		$	162,220		$	310,745		$	298,589
Plus (less):
Equity-based compensation expense		(7,129	)		(7,436	)		(14,048	)		(14,832	)
Transaction-related expenses		(2,887	)		(9,052	)		(7,655	)		(13,171	)
Debt extinguishment costs		—			(810	)		(940	)		(810	)
Interest expense, net		(45,812	)		(43,505	)		(91,055	)		(86,262	)
Depreciation and amortization		(39,928	)		(35,201	)		(79,701	)		(68,814	)
Income before income taxes	$	69,258		$	66,216		$	117,346		$	114,700

	U.S. Facilities		U.K. Facilities			Corporate and Other		Consolidated
Goodwill:
Balance at January 1, 2018	$	2,042,592	$	708,582		$	—	$	2,751,174
Increase from contribution of redeemable noncontrolling interests		2,244		—			—		2,244
Foreign currency translation loss		—		(14,877	)		—		(14,877	)
Prior year purchase price adjustments		—		762			—		762
Balance at June 30, 2018	$	2,044,836	$	694,467		$	—	$	2,739,303

	June 30, 2018		December 31, 2017
Assets (2):
U.S. Facilities	$	3,694,600	$	3,567,126
U.K. Facilities		2,599,911		2,647,150
Corporate and Other		208,636		210,226
	$	6,503,147	$	6,424,502

(1)

Segment EBITDA is defined as income before provision for income taxes, equity-based compensation expense, transaction-related expenses, debt extinguishment costs, interest expense and depreciation and amortization. The Company uses Segment EBITDA as an analytical indicator to measure the performance of the Company’s segments and to develop strategic objectives and operating plans for those segments. Segment EBITDA is commonly used as an analytical indicator within the health care industry, and also serves as a measure of leverage capacity and debt service ability. Segment EBITDA should not be considered as a measure of financial performance under GAAP, and the items excluded from Segment EBITDA are significant components in understanding and assessing financial performance. Because Segment EBITDA is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, Segment EBITDA, as presented, may not be comparable to other similarly titled measures of other companies.

(2)

Assets include property and equipment for the U.S. Facilities of $1.3 billion, U.K. Facilities of $1.8 billion and corporate and other of $50.4 million at June 30, 2018. Assets include property and equipment for the U.S. Facilities of $1.2 billion, U.K. Facilities of $1.8 billion and corporate and other of $49.2 million at December 31, 2017.

Accumulated Other Comprehensive Loss

6 Months Ended

Jun. 30, 2018

Equity [Abstract]

Accumulated Other Comprehensive Loss

17.	Accumulated Other Comprehensive Loss

The components of accumulated other comprehensive loss are as follows (in thousands):

	Foreign Currency Translation Adjustments			Change in Fair Value of Derivative Instruments		Pension Plan			Total
Balance at December 31, 2017	$	(376,740	)	$	7,167	$	(4,545	)	$	(374,118	)
Foreign currency translation (loss) gain		(50,916	)		—		97			(50,819	)
Gain on derivative instruments, net of tax of $3.2 million		—			9,054		—			9,054
Balance at June 30, 2018	$	(427,656	)	$	16,221	$	(4,448	)	$	(415,883	)

Financial Information for the Company and Its Subsidiaries

6 Months Ended

Jun. 30, 2018

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Financial Information for the Company and Its Subsidiaries

18.	Financial Information for the Company and Its Subsidiaries

The Company conducts substantially all of its business through its subsidiaries. The 6.125% Senior Notes, 5.125% Senior Notes, 5.625% Senior Notes and 6.500% Senior Notes are jointly and severally guaranteed on an unsecured senior basis by all of the Company’s subsidiaries that guarantee the Company’s obligations under the Amended and Restated Senior Credit Facility. Presented below is condensed consolidating financial information for the Company and its subsidiaries at June 30, 2018 and December 31, 2017, and for the three and six months ended June 30, 2018 and 2017. The information segregates the parent company (Acadia Healthcare Company, Inc.), the combined wholly-owned subsidiary guarantors, the combined non-guarantor subsidiaries and eliminations.

Acadia Healthcare Company, Inc.

Condensed Consolidating Balance Sheets

June 30, 2018

(In thousands)

	Parent		Combined Subsidiary Guarantors		Combined Non- Guarantors		Consolidating Adjustments			Total Consolidated Amounts
Current assets:
Cash and cash equivalents	$	—	$	59,979	$	19,484	$	—		$	79,463
Accounts receivable, net		—		253,954		75,302		—			329,256
Other current assets		—		56,961		23,542		—			80,503
Total current assets		—		370,894		118,328		—			489,222
Property and equipment, net		—		1,161,630		1,941,701		—			3,103,331
Goodwill		—		1,936,056		803,247		—			2,739,303
Intangible assets, net		—		58,295		33,271		—			91,566
Deferred tax assets		931		—		3,664		(931	)		3,664
Derivative instruments assets		24,989		—		—		—			24,989
Investment in subsidiaries		5,515,341		—		—		(5,515,341	)		—
Other assets		343,990		41,952		6,127		(340,997	)		51,072
Total assets	$	5,885,251	$	3,568,827	$	2,906,338	$	(5,857,269	)	$	6,503,147

Current liabilities:
Current portion of long-term debt	$	32,984	$	—	$	280	$	—		$	33,264
Accounts payable		—		86,317		43,911		—			130,228
Accrued salaries and benefits		—		73,543		29,297		—			102,840
Other accrued liabilities		32,985		31,526		63,275		—			127,786
Total current liabilities		65,969		191,386		136,763		—			394,118
Long-term debt		3,165,981		—		362,804		(340,997	)		3,187,788
Deferred tax liabilities		—		25,311		53,960		(931	)		78,340
Other liabilities		—		104,283		56,526		—			160,809
Total liabilities		3,231,950		320,980		610,053		(341,928	)		3,821,055
Redeemable noncontrolling interests		—		—		28,791		—			28,791
Total equity		2,653,301		3,247,847		2,267,494		(5,515,341	)		2,653,301
Total liabilities and equity	$	5,885,251	$	3,568,827	$	2,906,338	$	(5,857,269	)	$	6,503,147

Acadia Healthcare Company, Inc.

Condensed Consolidating Balance Sheets

December 31, 2017

(In thousands)

	Parent		Combined Subsidiary Guarantors		Combined Non- Guarantors		Consolidating Adjustments			Total Consolidated Amounts
Current assets:
Cash and cash equivalents	$	—	$	46,860	$	20,430	$	—		$	67,290
Accounts receivable, net		—		230,890		66,035		—			296,925
Other current assets		—		85,746		21,589		—			107,335
Total current assets		—		363,496		108,054		—			471,550
Property and equipment, net		—		1,086,802		1,961,328		—			3,048,130
Goodwill		—		1,936,057		815,117		—			2,751,174
Intangible assets, net		—		57,628		29,720		—			87,348
Deferred tax assets		2,370		—		3,731		(2,370	)		3,731
Derivative instruments assets		12,997		—		—		—			12,997
Investment in subsidiaries		5,429,386		—		—		(5,429,386	)		—
Other assets		381,913		38,860		7,807		(379,008	)		49,572
Total assets	$	5,826,666	$	3,482,843	$	2,925,757	$	(5,810,764	)	$	6,424,502

Current liabilities:
Current portion of long-term debt	$	34,550	$	—	$	280	$	—		$	34,830
Accounts payable		—		70,767		31,532		—			102,299
Accrued salaries and benefits		—		69,057		29,990		—			99,047
Other accrued liabilities		36,196		27,676		77,341		—			141,213
Total current liabilities		70,746		167,500		139,143		—			377,389
Long-term debt		3,183,049		—		401,017		(379,008	)		3,205,058
Deferred tax liabilities		—		27,975		54,728		(2,370	)		80,333
Other liabilities		—		103,112		63,322		—			166,434
Total liabilities		3,253,795		298,587		658,210		(381,378	)		3,829,214
Redeemable noncontrolling interests		—		—		22,417		—			22,417
Total equity		2,572,871		3,184,256		2,245,130		(5,429,386	)		2,572,871
Total liabilities and equity	$	5,826,666	$	3,482,843	$	2,925,757	$	(5,810,764	)	$	6,424,502

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income (Loss)

Three Months Ended June 30, 2018

(In thousands)

	Parent			Combined Subsidiary Guarantors		Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue	$	—		$	453,782	$	311,956		$	—		$	765,738
Salaries, wages and benefits		7,129			239,999		169,613			—			416,741
Professional fees		—			24,677		28,784			—			53,461
Supplies		—			19,292		10,841			—			30,133
Rents and leases		—			8,311		11,925			—			20,236
Other operating expenses		—			55,258		32,024			—			87,282
Depreciation and amortization		—			18,611		21,317			—			39,928
Interest expense, net		15,465			23,602		6,745			—			45,812
Transaction-related expenses		—			2,671		216			—			2,887
Total expenses		22,594			392,421		281,465			—			696,480
(Loss) income before income taxes		(22,594	)		61,361		30,491			—			69,258
Equity in earnings of subsidiaries		75,752			—		—			(75,752	)		—
(Benefit from) provision for income taxes		(5,732	)		11,442		4,658			—			10,368
Net income (loss)		58,890			49,919		25,833			(75,752	)		58,890
Net gain attributable to noncontrolling interests		—			—		(54	)		—			(54	)
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$	58,890		$	49,919	$	25,779		$	(75,752	)	$	58,836
Other comprehensive (loss) income:
Foreign currency translation loss		—			—		(143,599	)		—			(143,599	)
Gain on derivative instruments		29,107			—		—			—			29,107
Other comprehensive (loss) income		29,107			—		(143,599	)		—			(114,492	)
Comprehensive income (loss) attributable to Acadia Healthcare Company, Inc.	$	87,997		$	49,919	$	(117,820	)	$	(75,752	)	$	(55,656	)

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income (Loss)

Three Months Ended June 30, 2017

(In thousands)

	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue before provision for doubtful accounts	$	—		$	444,718		$	280,925		$	—		$	725,643
Provision for doubtful accounts		—			(8,483	)		(1,264	)		—			(9,747	)
Revenue		—			436,235			279,661			—			715,896
Salaries, wages and benefits		7,436			225,775			150,384			—			383,595
Professional fees		—			23,337			22,984			—			46,321
Supplies		—			19,050			9,589			—			28,639
Rents and leases		—			8,501			10,934			—			19,435
Other operating expenses		—			54,488			28,634			—			83,122
Depreciation and amortization		—			16,404			18,797			—			35,201
Interest expense, net		15,091			19,265			9,149			—			43,505
Debt extinguishment costs		810			—			—			—			810
Transaction-related expenses		—			2,570			6,482			—			9,052
Total expenses		23,337			369,390			256,953			—			649,680
(Loss) income before income taxes		(23,337	)		66,845			22,708			—			66,216
Equity in earnings of subsidiaries		61,453			—			—			(61,453	)		—
(Benefit from) provision for income taxes		(11,522	)		23,852			4,248			—			16,578
Net income (loss)		49,638			42,993			18,460			(61,453	)		49,638
Net loss attributable to noncontrolling interests		—			—			(8	)		—			(8	)
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$	49,638		$	42,993		$	18,452		$	(61,453	)	$	49,630
Other comprehensive (loss) income:
Foreign currency translation gain		—			—			92,076			—			92,076
Loss on derivative instruments		(9,084	)		—			—			—			(9,084	)
Other comprehensive (loss) income		(9,084	)		—			92,076			—			82,992
Comprehensive income (loss) attributable to Acadia Healthcare Company, Inc.	$	40,554		$	42,993		$	110,528		$	(61,453	)	$	132,622

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income (Loss)

Six Months Ended June 30, 2018

(In thousands)

	Parent			Combined Subsidiary Guarantors		Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue	$	—		$	889,407	$	618,572		$	—		$	1,507,979
Salaries, wages and benefits		14,048			479,051		335,170			—			828,269
Professional fees		—			48,948		58,531			—			107,479
Supplies		—			38,004		21,493			—			59,497
Rents and leases		—			16,550		23,974			—			40,524
Other operating expenses		—			111,428		64,085			—			175,513
Depreciation and amortization		—			36,783		42,918			—			79,701
Interest expense, net		30,082			47,186		13,787			—			91,055
Debt extinguishment costs		940			—		—			—			940
Transaction-related expenses		—			6,680		975			—			7,655
Total expenses		45,070			784,630		560,933			—			1,390,633
(Loss) income before income taxes		(45,070	)		104,777		57,639			—			117,346
Equity in earnings of subsidiaries		143,350			—		—			(143,350	)		—
(Benefit from) provision for income taxes		(11,484	)		11,319		7,747			—			7,582
Net income (loss)		109,764			93,458		49,892			(143,350	)		109,764
Net gain attributable to noncontrolling interests		—			—		(109	)		—			(109	)
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$	109,764		$	93,458	$	49,783		$	(143,350	)	$	109,655
Other comprehensive (loss) income:
Foreign currency translation loss		—			—		(50,819	)		—			(50,819	)
Gain on derivative instruments		9,054			—		—			—			9,054
Other comprehensive (loss) income		9,054			—		(50,819	)		—			(41,765	)
Comprehensive income (loss) attributable to Acadia Healthcare Company, Inc.	$	118,818		$	93,458	$	(1,036	)	$	(143,350	)	$	67,890

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income (Loss)

Six Months Ended June 30, 2017

(In thousands)

	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue before provision for doubtful accounts	$	—		$	871,514		$	543,470		$	—		$	1,414,984
Provision for doubtful accounts		—			(17,697	)		(2,197	)		—			(19,894	)
Revenue		—			853,817			541,273			—			1,395,090
Salaries, wages and benefits		14,832			450,205			294,979			—			760,016
Professional fees		—			45,411			44,319			—			89,730
Supplies		—			37,659			18,689			—			56,348
Rents and leases		—			17,012			21,394			—			38,406
Other operating expenses		—			109,519			57,314			—			166,833
Depreciation and amortization		—			31,955			36,859			—			68,814
Interest expense, net		30,459			37,750			18,053			—			86,262
Debt extinguishment costs		810			—			—			—			810
Transaction-related expenses		—			4,008			9,163			—			13,171
Total expenses		46,101			733,519			500,770			—			1,280,390
(Loss) income before income taxes		(46,101	)		120,298			40,503			—			114,700
Equity in earnings of subsidiaries		108,006			—			—			(108,006	)		—
(Benefit from) provision for income taxes		(22,506	)		44,922			7,873			—			30,289
Net income (loss)		84,411			75,376			32,630			(108,006	)		84,411
Net loss attributable to noncontrolling interests		—			—			177			—			177
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$	84,411		$	75,376		$	32,807		$	(108,006	)	$	84,588
Other comprehensive (loss) income:
Foreign currency translation gain		—			—			119,122			—			119,122
Loss on derivative instruments		(14,952	)		—			—			—			(14,952	)
Other comprehensive (loss) income		(14,952	)		—			119,122			—			104,170
Comprehensive income (loss) attributable to Acadia Healthcare Company, Inc.	$	69,459		$	75,376		$	151,929		$	(108,006	)	$	188,758

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Cash Flows

Six Months Ended June 30, 2018

(In thousands)

	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Operating activities:
Net income (loss)	$	109,764		$	93,458		$	49,892		$	(143,350	)	$	109,764
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Equity in earnings of subsidiaries		(143,350	)		—			—			143,350			—
Depreciation and amortization		—			36,783			42,918			—			79,701
Amortization of debt issuance costs		5,326			—			(202	)		—			5,124
Equity-based compensation expense		14,048			—			—			—			14,048
Deferred income taxes		1,438			(5,843	)		427			—			(3,978	)
Debt extinguishment costs		940			—			—			—			940
Other		240			1,149			(349	)		—			1,040
Change in operating assets and liabilities:
Accounts receivable, net		—			(23,064	)		(3,040	)		—			(26,104	)
Other current assets		—			12,197			(2,244	)		—			9,953
Other assets		4,514			2,689			72			(4,514	)		2,761
Accounts payable and other accrued liabilities		—			27,859			(6,793	)		—			21,066
Accrued salaries and benefits		—			4,487			(123	)		—			4,364
Other liabilities		—			3,002			(3,795	)		—			(793	)
Net cash (used in) provided by continuing operating activities		(7,080	)		152,717			76,763			(4,514	)		217,886
Net cash used in discontinued operating activities		—			(572	)		—			—			(572	)
Net cash (used in) provided by operating activities		(7,080	)		152,145			76,763			(4,514	)		217,314
Investing activities:
Cash paid for capital expenditures		—			(97,186	)		(64,369	)		—			(161,555	)
Cash paid for real estate acquisitions		—			(8,857	)		—			—			(8,857	)
Other		—			(5,759	)		2,422			—			(3,337	)
Net cash used in investing activities		—			(111,802	)		(61,947	)		—			(173,749	)
Financing activities:
Principal payments on long-term debt		(23,246	)		(169	)		(4,345	)		4,514			(23,246	)
Common stock withheld for minimum statutory taxes, net		(2,134	)		—			—			—			(2,134	)
Other		(1,742	)		(1,924	)		(1,506	)		—			(5,172	)
Cash provided by (used in) intercompany activity		34,202			(25,131	)		(9,071	)		—			—
Net provided by (used in) in financing activities		7,080			(27,224	)		(14,922	)		4,514			(30,552	)
Effect of exchange rate changes on cash		—			—			(840	)		—			(840	)
Net increase (decrease) in cash and cash equivalents		—			13,119			(946	)		—			12,173
Cash and cash equivalents at beginning of the period		—			46,860			20,430			—			67,290
Cash and cash equivalents at end of the period	$	—		$	59,979		$	19,484		$	—		$	79,463

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Cash Flows

Six Months Ended June 30, 2017

(In thousands)

	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Operating activities:
Net income (loss)	$	84,411		$	75,376		$	32,630		$	(108,006	)	$	84,411
Adjustments to reconcile net income (loss) to net cash provided by (used in) continuing operating activities:
Equity in earnings of subsidiaries		(108,006	)		—			—			108,006			—
Depreciation and amortization		—			31,955			36,859			—			68,814
Amortization of debt issuance costs		5,053			—			(208	)		—			4,845
Equity-based compensation expense		14,832			—			—			—			14,832
Deferred income taxes		1,610			12,268			3,218			—			17,096
Debt extinguishment costs		810			—			—			—			810
Other		2,692			1,181			2,685			—			6,558
Change in operating assets and liabilities:
Accounts receivable, net		—			(13,423	)		(8,981	)		—			(22,404	)
Other current assets		—			(3,564	)		24,021			—			20,457
Other assets		3,397			1,705			104			(3,397	)		1,809
Accounts payable and other accrued liabilities		—			3,747			(8,640	)		—			(4,893	)
Accrued salaries and benefits		—			(6,591	)		(2,566	)		—			(9,157	)
Other liabilities		—			1,625			3,632			—			5,257
Net cash provided by (used in) continuing operating activities		4,799			104,279			82,754			(3,397	)		188,435
Net cash used in discontinued operating activities		—			(829	)		—			—			(829	)
Net cash provided by (used in) operating activities		4,799			103,450			82,754			(3,397	)		187,606
Investing activities:
Cash paid for capital expenditures		—			(71,274	)		(46,247	)		—			(117,521	)
Cash paid for real estate acquisitions		—			(22,850	)		—			—			(22,850	)
Other		—			(7,543	)		1,605			—			(5,938	)
Net cash used in investing activities		—			(101,667	)		(44,642	)		—			(146,309	)
Financing activities:
Principal payments on long-term debt		(17,275	)		—			(3,397	)		3,397			(17,275	)
Common stock withheld for minimum statutory taxes, net		(3,678	)		—			—			—			(3,678	)
Other		—			(2,270	)		—			—			(2,270	)
Cash provided by (used in) intercompany activity		16,154			32,629			(48,783	)		—			—
Net (used in) provided by in financing activities		(4,799	)		30,359			(52,180	)		3,397			(23,223	)
Effect of exchange rate changes on cash		—			—			4,297			—			4,297
Net decrease in cash and cash equivalents		—			32,142			(9,771	)		—			22,371
Cash and cash equivalents at beginning of the period		—			15,681			41,382			—			57,063
Cash and cash equivalents at end of the period	$	—		$	47,823		$	31,611		$	—		$	79,434

Revenue (Tables)

6 Months Ended

Jun. 30, 2018

Summary of the Activity in Unearned Revenue in the U.K. Facilities

A summary of the activity in unearned revenue in the U.K. Facilities is as follows (in thousands):

Balance at December 31, 2017	$	30,812
Payments received		84,541
Revenue recognized		(82,580	)
Foreign currency translation loss		(1,340	)
Balance at June 30, 2018	$	31,433

U.S. Facilities [Member]

Schedule of Revenue Attributed to Each Category

The table below presents total U.S. revenue attributed to each category (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
Acute inpatient psychiatric facilities	$	203,535	$	193,989	$	399,426	$	378,676
Specialty treatment facilities		192,894		182,748		377,429		357,945
Residential treatment centers		74,133		73,180		145,690		142,467
Outpatient community-based services		10,908		11,497		21,330		22,549
Revenue	$	481,470	$	461,414	$	943,875	$	901,637

Schedule of Revenue Generated by Each Payor Type

The following table presents revenue generated by each payor type (in thousands):

	Three Months Ended June 30,					Six Months Ended June 30,
	2018		2017			2018		2017
Commercial	$	147,279	$	149,493		$	284,898	$	288,948
Medicare		69,508		71,559			136,779		139,399
Medicaid		225,567		197,279			438,846		388,113
Self-Pay		33,379		43,561			70,286		87,243
Other		5,737		9,269			13,066		17,822
Revenue before provision for doubtful accounts		481,470		471,161			943,875		921,525
Provision for doubtful accounts		—		(9,747	)		—		(19,888	)
Revenue	$	481,470	$	461,414		$	943,875	$	901,637

U.K. Facilities [Member]

Schedule of Revenue Attributed to Each Category

The table below presents total U.K. revenue attributed to each category (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
Healthcare facilities	$	159,060	$	141,187	$	313,860	$	273,285
Education and Children’s Services		49,310		42,199		98,643		81,896
Adult Care facilities		75,898		71,096		151,601		138,272
Revenue	$	284,268	$	254,482	$	564,104	$	493,453

Schedule of Revenue Generated by Each Payor Type

The following table presents revenue generated by each payor type (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
U.K. public funded sources	$	256,881	$	226,380	$	510,175	$	441,845
Self-Pay		27,272		23,889		52,340		46,090
Other		115		4,213		1,589		5,524
Revenue before provision for doubtful accounts		284,268		254,482		564,104		493,459
Provision for doubtful accounts		—		—		—		(6	)
Revenue	$	284,268	$	254,482	$	564,104	$	493,453

Accounting Standards Update 2014-09 [Member]

Summary of Impact of Adoption of Accounting Standards

The impact of adopting ASU 2014-09 on the condensed consolidated statements of income for the three and six months ended June 30, 2018 was as follows (in thousands):

	Three Months Ended June 30, 2018					Six Months Ended June 30, 2018
	As Reported		Prior to Adopting ASU 2014-09			As Reported		Prior to Adopting ASU 2014-09
Revenue before provision for doubtful accounts	$	765,738	$	775,203		$	1,507,979	$	1,525,704
Provision for doubtful accounts		—		(9,465	)		—		(17,725	)
Revenue	$	765,738	$	765,738		$	1,507,979	$	1,507,979

Earnings Per Share (Tables)

6 Months Ended

Jun. 30, 2018

Earnings Per Share [Abstract]

Computation of Basic and Diluted Earnings Per Share

The following table sets forth the computation of basic and diluted earnings per share for the three and six months ended June 30, 2018 and 2017 (in thousands, except per share amounts):

	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
Numerator:
Net income attributable to Acadia Healthcare Company, Inc.	$	58,836	$	49,630	$	109,655	$	84,588
Denominator:
Weighted average shares outstanding for basic earnings per share		87,303		86,954		87,205		86,859
Effect of dilutive instruments		164		126		146		138
Shares used in computing diluted earnings per common share		87,467		87,080		87,351		86,997
Earnings per share attributable to Acadia Healthcare Company, Inc. stockholders:
Basic	$	0.67	$	0.57	$	1.26	$	0.97
Diluted	$	0.67	$	0.57	$	1.26	$	0.97

Other Intangible Assets (Tables)

6 Months Ended

Jun. 30, 2018

Goodwill And Intangible Assets Disclosure [Abstract]

Other Identifiable Intangible Assets and Related Accumulated Amortization

Other identifiable intangible assets and related accumulated amortization consisted of the following at June 30, 2018 and December 31, 2017 (in thousands):

	Gross Carrying Amount				Accumulated Amortization
	June 30, 2018		December 31, 2017		June 30, 2018			December 31, 2017
Intangible assets subject to amortization:
Contract intangible assets	$	2,100	$	2,100	$	(2,100	)	$	(2,100	)
Non-compete agreements		1,147		1,147		(1,147	)		(1,147	)
		3,247		3,247		(3,247	)		(3,247	)
Intangible assets not subject to amortization:
Licenses and accreditations		12,772		12,266		—			—
Trade names		61,960		60,586		—			—
Certificates of need		16,834		14,496		—			—
		91,566		87,348		—			—
Total	$	94,813	$	90,595	$	(3,247	)	$	(3,247	)

Property and Equipment (Tables)

6 Months Ended

Jun. 30, 2018

Property Plant And Equipment [Abstract]

Summary of Property and Equipment

Property and equipment consists of the following at June 30, 2018 and December 31, 2017 (in thousands):

	June 30, 2018			December 31, 2017
Land	$	451,264		$	450,342
Building and improvements		2,440,139			2,370,918
Equipment		438,033			400,596
Construction in progress		195,697			173,693
		3,525,133			3,395,549
Less accumulated depreciation		(421,802	)		(347,419	)
Property and equipment, net	$	3,103,331		$	3,048,130

Long-Term Debt (Tables)

6 Months Ended

Jun. 30, 2018

Debt Disclosure [Abstract]

Components of Long-Term Debt

Long-term debt consisted of the following (in thousands):

	June 30, 2018			December 31, 2017
Amended and Restated Senior Credit Facility:
Senior Secured Term A Loans	$	375,250		$	380,000
Senior Secured Term B Loans		1,379,904			1,398,400
Senior Secured Revolving Line of Credit		—			—
6.125% Senior Notes due 2021		150,000			150,000
5.125% Senior Notes due 2022		300,000			300,000
5.625% Senior Notes due 2023		650,000			650,000
6.500% Senior Notes due 2024		390,000			390,000
9.0% and 9.5% Revenue Bonds		21,920			21,920
Less: unamortized debt issuance costs, discount and premium		(46,022	)		(50,432	)
		3,221,052			3,239,888
Less: current portion		(33,264	)		(34,830	)
Long-term debt	$	3,187,788		$	3,205,058

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

+ Details

Equity-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2018

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock Option Activity

Stock option activity during 2017 and 2018 was as follows (aggregate intrinsic value in thousands):

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Options outstanding at January 1, 2017		1,000,946		$	49.42		7.80	$	8,166
Options granted		259,300			42.25		9.30		205
Options exercised		(87,367	)		25.92	N/A			1,636
Options cancelled		(198,313	)		54.71	N/A		N/A
Options outstanding at December 31, 2017		974,566			47.89		7.46		3,802
Options granted		353,800			37.36		7.85		137
Options exercised		(8,689	)		25.87	N/A			134
Options cancelled		(86,112	)		51.97	N/A		N/A
Options outstanding at June 30, 2018		1,233,565		$	44.70		7.42	$	2,764
Options exercisable at December 31, 2017		405,634		$	41.20		6.05	$	3,549
Options exercisable at June 30, 2018		541,589		$	44.53		6.11	$	2,494

Schedule of Stock Options Valuation Assumptions

The following table summarizes the grant-date fair value of options and the assumptions used to develop the fair value estimates for options granted during the six months ended June 30, 2018 and year ended December 31, 2017:

	June 30, 2018			December 31, 2017
Weighted average grant-date fair value of options	$	13.61		$	14.39
Risk-free interest rate		2.2	%		2.0	%
Expected volatility		38	%		33	%
Expected life (in years)		5.0			5.5

Restricted Stock Activity

Restricted stock activity during 2017 and 2018 was as follows:

	Number of Shares			Weighted Average Grant-Date Fair Value
Unvested at January 1, 2017		844,419		$	55.76
Granted		404,224			42.38
Cancelled		(145,981	)		55.03
Vested		(292,794	)		53.07
Unvested at December 31, 2017		809,868		$	50.19
Granted		441,837			36.51
Cancelled		(58,217	)		49.25
Vested		(245,814	)		53.44
Unvested at June 30, 2018		947,674		$	43.03

Restricted Stock Unit Activity

Restricted stock unit activity during 2017 and 2018 was as follows:

	Number of Units			Weighted Average Grant-Date Fair Value
Unvested at January 1, 2017		273,599		$	59.68
Granted		219,840			43.23
Cancelled		—			—
Vested		(132,530	)		58.67
Unvested at December 31, 2017		360,909		$	50.04
Granted		285,358			42.26
Cancelled		(89,173	)		55.44
Vested		(72,983	)		49.64
Unvested at June 30, 2018		484,111		$	44.52

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2018

Fair Value Disclosures [Abstract]

Carrying Amounts and Fair Values of Company's Amended and Restated Senior Credit Facilities and Contingent Consideration Liabilities

	Carrying Amount				Fair Value
	June 30, 2018		December 31, 2017		June 30, 2018		December 31, 2017
Amended and Restated Senior Credit Facility	$	1,728,688	$	1,749,185	$	1,728,688	$	1,749,185
6.125% Senior Notes due 2021	$	148,373	$	148,098	$	149,857	$	150,134
5.125% Senior Notes due 2022	$	296,555	$	296,174	$	295,814	$	296,914
5.625% Senior Notes due 2023	$	642,580	$	641,891	$	647,399	$	651,519
6.500% Senior Notes due 2024	$	382,769	$	382,251	$	392,338	$	397,541
9.0% and 9.5% Revenue Bonds	$	22,087	$	22,289	$	22,087	$	22,289
Derivative instrument assets	$	24,989	$	12,997	$	24,989	$	12,997

Noncontrolling Interests (Tables)

6 Months Ended

Jun. 30, 2018

Noncontrolling Interest [Abstract]

Summary of Redeemable Noncontrolling Interests

The components of redeemable noncontrolling interests are as follows (in thousands):

Balance at December 31, 2017	$	22,417
Contribution of redeemable noncontrolling interests		6,265
Net income attributable to noncontrolling interests		109
Balance at June 30, 2018	$	28,791

Other Current Assets (Tables)

6 Months Ended

Jun. 30, 2018

Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]

Other Current Assets

Other current assets consisted of the following (in thousands):

	June 30, 2018		December 31, 2017
Prepaid expenses	$	28,379	$	27,320
Other receivables		29,791		30,455
Workers’ compensation deposits – current portion		10,000		10,000
Inventory		4,733		4,787
Income taxes receivable		3,885		15,056
Insurance receivable-current portion		1,688		17,588
Other		2,027		2,129
Other current assets	$	80,503	$	107,335

Other Accrued Liabilities (Tables)

6 Months Ended

Jun. 30, 2018

Other Liabilities Disclosure [Abstract]

Summary of Other Accrued Liabilities

Other accrued liabilities consisted of the following (in thousands):

	June 30, 2018		December 31, 2017
Accrued interest	$	33,156	$	36,370
Unearned income		32,362		31,342
Accrued expenses		32,113		37,268
Income taxes payable		8,966		1,012
Insurance liability – current portion		6,888		22,788
Accrued property taxes		4,530		3,945
Other		9,771		8,488
Other accrued liabilities	$	127,786	$	141,213

Segment Information (Tables)

6 Months Ended

Jun. 30, 2018

Summary of Reconciliation of Segment EBITDA to Income from Continuing Operations

The following tables set forth the financial information by operating segment, including a reconciliation of Segment EBITDA to income before income taxes (in thousands):

	Three Months Ended June 30,						Six Months Ended June 30,
	2018			2017			2018			2017
Revenue:
U.S. Facilities	$	481,470		$	461,414		$	943,875		$	901,637
U.K. Facilities		284,268			254,482			564,104			493,453
Corporate and Other		—			—			—			—
	$	765,738		$	715,896		$	1,507,979		$	1,395,090
Segment EBITDA (1):
U.S. Facilities	$	130,002		$	128,361		$	247,126		$	240,506
U.K. Facilities		54,194			52,090			105,346			96,276
Corporate and Other		(19,182	)		(18,231	)		(41,727	)		(38,193	)
	$	165,014		$	162,220		$	310,745		$	298,589

	Three Months Ended June 30,						Six Months Ended June 30,
	2018			2017			2018			2017
Segment EBITDA (1)	$	165,014		$	162,220		$	310,745		$	298,589
Plus (less):
Equity-based compensation expense		(7,129	)		(7,436	)		(14,048	)		(14,832	)
Transaction-related expenses		(2,887	)		(9,052	)		(7,655	)		(13,171	)
Debt extinguishment costs		—			(810	)		(940	)		(810	)
Interest expense, net		(45,812	)		(43,505	)		(91,055	)		(86,262	)
Depreciation and amortization		(39,928	)		(35,201	)		(79,701	)		(68,814	)
Income before income taxes	$	69,258		$	66,216		$	117,346		$	114,700

Summary of Assets by Operating Segment

	June 30, 2018		December 31, 2017
Assets (2):
U.S. Facilities	$	3,694,600	$	3,567,126
U.K. Facilities		2,599,911		2,647,150
Corporate and Other		208,636		210,226
	$	6,503,147	$	6,424,502

(1)

(2)

Goodwill [Member]

Summary of Assets by Operating Segment

	U.S. Facilities		U.K. Facilities			Corporate and Other		Consolidated
Goodwill:
Balance at January 1, 2018	$	2,042,592	$	708,582		$	—	$	2,751,174
Increase from contribution of redeemable noncontrolling interests		2,244		—			—		2,244
Foreign currency translation loss		—		(14,877	)		—		(14,877	)
Prior year purchase price adjustments		—		762			—		762
Balance at June 30, 2018	$	2,044,836	$	694,467		$	—	$	2,739,303

Accumulated Other Comprehensive Loss (Tables)

6 Months Ended

Jun. 30, 2018

Equity [Abstract]

Components Of Accumulated Other Comprehensive Loss

The components of accumulated other comprehensive loss are as follows (in thousands):

	Foreign Currency Translation Adjustments			Change in Fair Value of Derivative Instruments		Pension Plan			Total
Balance at December 31, 2017	$	(376,740	)	$	7,167	$	(4,545	)	$	(374,118	)
Foreign currency translation (loss) gain		(50,916	)		—		97			(50,819	)
Gain on derivative instruments, net of tax of $3.2 million		—			9,054		—			9,054
Balance at June 30, 2018	$	(427,656	)	$	16,221	$	(4,448	)	$	(415,883	)

Financial Information for the Company and Its Subsidiaries (Tables)

6 Months Ended

Jun. 30, 2018

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Summary of Condensed Consolidating Balance Sheets

Acadia Healthcare Company, Inc.

Condensed Consolidating Balance Sheets

June 30, 2018

(In thousands)

	Parent		Combined Subsidiary Guarantors		Combined Non- Guarantors		Consolidating Adjustments			Total Consolidated Amounts
Current assets:
Cash and cash equivalents	$	—	$	59,979	$	19,484	$	—		$	79,463
Accounts receivable, net		—		253,954		75,302		—			329,256
Other current assets		—		56,961		23,542		—			80,503
Total current assets		—		370,894		118,328		—			489,222
Property and equipment, net		—		1,161,630		1,941,701		—			3,103,331
Goodwill		—		1,936,056		803,247		—			2,739,303
Intangible assets, net		—		58,295		33,271		—			91,566
Deferred tax assets		931		—		3,664		(931	)		3,664
Derivative instruments assets		24,989		—		—		—			24,989
Investment in subsidiaries		5,515,341		—		—		(5,515,341	)		—
Other assets		343,990		41,952		6,127		(340,997	)		51,072
Total assets	$	5,885,251	$	3,568,827	$	2,906,338	$	(5,857,269	)	$	6,503,147

Current liabilities:
Current portion of long-term debt	$	32,984	$	—	$	280	$	—		$	33,264
Accounts payable		—		86,317		43,911		—			130,228
Accrued salaries and benefits		—		73,543		29,297		—			102,840
Other accrued liabilities		32,985		31,526		63,275		—			127,786
Total current liabilities		65,969		191,386		136,763		—			394,118
Long-term debt		3,165,981		—		362,804		(340,997	)		3,187,788
Deferred tax liabilities		—		25,311		53,960		(931	)		78,340
Other liabilities		—		104,283		56,526		—			160,809
Total liabilities		3,231,950		320,980		610,053		(341,928	)		3,821,055
Redeemable noncontrolling interests		—		—		28,791		—			28,791
Total equity		2,653,301		3,247,847		2,267,494		(5,515,341	)		2,653,301
Total liabilities and equity	$	5,885,251	$	3,568,827	$	2,906,338	$	(5,857,269	)	$	6,503,147

Acadia Healthcare Company, Inc.

Condensed Consolidating Balance Sheets

December 31, 2017

(In thousands)

	Parent		Combined Subsidiary Guarantors		Combined Non- Guarantors		Consolidating Adjustments			Total Consolidated Amounts
Current assets:
Cash and cash equivalents	$	—	$	46,860	$	20,430	$	—		$	67,290
Accounts receivable, net		—		230,890		66,035		—			296,925
Other current assets		—		85,746		21,589		—			107,335
Total current assets		—		363,496		108,054		—			471,550
Property and equipment, net		—		1,086,802		1,961,328		—			3,048,130
Goodwill		—		1,936,057		815,117		—			2,751,174
Intangible assets, net		—		57,628		29,720		—			87,348
Deferred tax assets		2,370		—		3,731		(2,370	)		3,731
Derivative instruments assets		12,997		—		—		—			12,997
Investment in subsidiaries		5,429,386		—		—		(5,429,386	)		—
Other assets		381,913		38,860		7,807		(379,008	)		49,572
Total assets	$	5,826,666	$	3,482,843	$	2,925,757	$	(5,810,764	)	$	6,424,502

Current liabilities:
Current portion of long-term debt	$	34,550	$	—	$	280	$	—		$	34,830
Accounts payable		—		70,767		31,532		—			102,299
Accrued salaries and benefits		—		69,057		29,990		—			99,047
Other accrued liabilities		36,196		27,676		77,341		—			141,213
Total current liabilities		70,746		167,500		139,143		—			377,389
Long-term debt		3,183,049		—		401,017		(379,008	)		3,205,058
Deferred tax liabilities		—		27,975		54,728		(2,370	)		80,333
Other liabilities		—		103,112		63,322		—			166,434
Total liabilities		3,253,795		298,587		658,210		(381,378	)		3,829,214
Redeemable noncontrolling interests		—		—		22,417		—			22,417
Total equity		2,572,871		3,184,256		2,245,130		(5,429,386	)		2,572,871
Total liabilities and equity	$	5,826,666	$	3,482,843	$	2,925,757	$	(5,810,764	)	$	6,424,502

Summary of Condensed Consolidating Statement of Comprehensive Income (Loss)

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income (Loss)

Three Months Ended June 30, 2018

(In thousands)

	Parent			Combined Subsidiary Guarantors		Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue	$	—		$	453,782	$	311,956		$	—		$	765,738
Salaries, wages and benefits		7,129			239,999		169,613			—			416,741
Professional fees		—			24,677		28,784			—			53,461
Supplies		—			19,292		10,841			—			30,133
Rents and leases		—			8,311		11,925			—			20,236
Other operating expenses		—			55,258		32,024			—			87,282
Depreciation and amortization		—			18,611		21,317			—			39,928
Interest expense, net		15,465			23,602		6,745			—			45,812
Transaction-related expenses		—			2,671		216			—			2,887
Total expenses		22,594			392,421		281,465			—			696,480
(Loss) income before income taxes		(22,594	)		61,361		30,491			—			69,258
Equity in earnings of subsidiaries		75,752			—		—			(75,752	)		—
(Benefit from) provision for income taxes		(5,732	)		11,442		4,658			—			10,368
Net income (loss)		58,890			49,919		25,833			(75,752	)		58,890
Net gain attributable to noncontrolling interests		—			—		(54	)		—			(54	)
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$	58,890		$	49,919	$	25,779		$	(75,752	)	$	58,836
Other comprehensive (loss) income:
Foreign currency translation loss		—			—		(143,599	)		—			(143,599	)
Gain on derivative instruments		29,107			—		—			—			29,107
Other comprehensive (loss) income		29,107			—		(143,599	)		—			(114,492	)
Comprehensive income (loss) attributable to Acadia Healthcare Company, Inc.	$	87,997		$	49,919	$	(117,820	)	$	(75,752	)	$	(55,656	)

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income (Loss)

Three Months Ended June 30, 2017

(In thousands)

	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue before provision for doubtful accounts	$	—		$	444,718		$	280,925		$	—		$	725,643
Provision for doubtful accounts		—			(8,483	)		(1,264	)		—			(9,747	)
Revenue		—			436,235			279,661			—			715,896
Salaries, wages and benefits		7,436			225,775			150,384			—			383,595
Professional fees		—			23,337			22,984			—			46,321
Supplies		—			19,050			9,589			—			28,639
Rents and leases		—			8,501			10,934			—			19,435
Other operating expenses		—			54,488			28,634			—			83,122
Depreciation and amortization		—			16,404			18,797			—			35,201
Interest expense, net		15,091			19,265			9,149			—			43,505
Debt extinguishment costs		810			—			—			—			810
Transaction-related expenses		—			2,570			6,482			—			9,052
Total expenses		23,337			369,390			256,953			—			649,680
(Loss) income before income taxes		(23,337	)		66,845			22,708			—			66,216
Equity in earnings of subsidiaries		61,453			—			—			(61,453	)		—
(Benefit from) provision for income taxes		(11,522	)		23,852			4,248			—			16,578
Net income (loss)		49,638			42,993			18,460			(61,453	)		49,638
Net loss attributable to noncontrolling interests		—			—			(8	)		—			(8	)
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$	49,638		$	42,993		$	18,452		$	(61,453	)	$	49,630
Other comprehensive (loss) income:
Foreign currency translation gain		—			—			92,076			—			92,076
Loss on derivative instruments		(9,084	)		—			—			—			(9,084	)
Other comprehensive (loss) income		(9,084	)		—			92,076			—			82,992
Comprehensive income (loss) attributable to Acadia Healthcare Company, Inc.	$	40,554		$	42,993		$	110,528		$	(61,453	)	$	132,622

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income (Loss)

Six Months Ended June 30, 2018

(In thousands)

	Parent			Combined Subsidiary Guarantors		Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue	$	—		$	889,407	$	618,572		$	—		$	1,507,979
Salaries, wages and benefits		14,048			479,051		335,170			—			828,269
Professional fees		—			48,948		58,531			—			107,479
Supplies		—			38,004		21,493			—			59,497
Rents and leases		—			16,550		23,974			—			40,524
Other operating expenses		—			111,428		64,085			—			175,513
Depreciation and amortization		—			36,783		42,918			—			79,701
Interest expense, net		30,082			47,186		13,787			—			91,055
Debt extinguishment costs		940			—		—			—			940
Transaction-related expenses		—			6,680		975			—			7,655
Total expenses		45,070			784,630		560,933			—			1,390,633
(Loss) income before income taxes		(45,070	)		104,777		57,639			—			117,346
Equity in earnings of subsidiaries		143,350			—		—			(143,350	)		—
(Benefit from) provision for income taxes		(11,484	)		11,319		7,747			—			7,582
Net income (loss)		109,764			93,458		49,892			(143,350	)		109,764
Net gain attributable to noncontrolling interests		—			—		(109	)		—			(109	)
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$	109,764		$	93,458	$	49,783		$	(143,350	)	$	109,655
Other comprehensive (loss) income:
Foreign currency translation loss		—			—		(50,819	)		—			(50,819	)
Gain on derivative instruments		9,054			—		—			—			9,054
Other comprehensive (loss) income		9,054			—		(50,819	)		—			(41,765	)
Comprehensive income (loss) attributable to Acadia Healthcare Company, Inc.	$	118,818		$	93,458	$	(1,036	)	$	(143,350	)	$	67,890

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income (Loss)

Six Months Ended June 30, 2017

(In thousands)

	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue before provision for doubtful accounts	$	—		$	871,514		$	543,470		$	—		$	1,414,984
Provision for doubtful accounts		—			(17,697	)		(2,197	)		—			(19,894	)
Revenue		—			853,817			541,273			—			1,395,090
Salaries, wages and benefits		14,832			450,205			294,979			—			760,016
Professional fees		—			45,411			44,319			—			89,730
Supplies		—			37,659			18,689			—			56,348
Rents and leases		—			17,012			21,394			—			38,406
Other operating expenses		—			109,519			57,314			—			166,833
Depreciation and amortization		—			31,955			36,859			—			68,814
Interest expense, net		30,459			37,750			18,053			—			86,262
Debt extinguishment costs		810			—			—			—			810
Transaction-related expenses		—			4,008			9,163			—			13,171
Total expenses		46,101			733,519			500,770			—			1,280,390
(Loss) income before income taxes		(46,101	)		120,298			40,503			—			114,700
Equity in earnings of subsidiaries		108,006			—			—			(108,006	)		—
(Benefit from) provision for income taxes		(22,506	)		44,922			7,873			—			30,289
Net income (loss)		84,411			75,376			32,630			(108,006	)		84,411
Net loss attributable to noncontrolling interests		—			—			177			—			177
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$	84,411		$	75,376		$	32,807		$	(108,006	)	$	84,588
Other comprehensive (loss) income:
Foreign currency translation gain		—			—			119,122			—			119,122
Loss on derivative instruments		(14,952	)		—			—			—			(14,952	)
Other comprehensive (loss) income		(14,952	)		—			119,122			—			104,170
Comprehensive income (loss) attributable to Acadia Healthcare Company, Inc.	$	69,459		$	75,376		$	151,929		$	(108,006	)	$	188,758

Summary of Condensed Consolidating Statement of Cash Flows

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Cash Flows

Six Months Ended June 30, 2018

(In thousands)

	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Operating activities:
Net income (loss)	$	109,764		$	93,458		$	49,892		$	(143,350	)	$	109,764
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Equity in earnings of subsidiaries		(143,350	)		—			—			143,350			—
Depreciation and amortization		—			36,783			42,918			—			79,701
Amortization of debt issuance costs		5,326			—			(202	)		—			5,124
Equity-based compensation expense		14,048			—			—			—			14,048
Deferred income taxes		1,438			(5,843	)		427			—			(3,978	)
Debt extinguishment costs		940			—			—			—			940
Other		240			1,149			(349	)		—			1,040
Change in operating assets and liabilities:
Accounts receivable, net		—			(23,064	)		(3,040	)		—			(26,104	)
Other current assets		—			12,197			(2,244	)		—			9,953
Other assets		4,514			2,689			72			(4,514	)		2,761
Accounts payable and other accrued liabilities		—			27,859			(6,793	)		—			21,066
Accrued salaries and benefits		—			4,487			(123	)		—			4,364
Other liabilities		—			3,002			(3,795	)		—			(793	)
Net cash (used in) provided by continuing operating activities		(7,080	)		152,717			76,763			(4,514	)		217,886
Net cash used in discontinued operating activities		—			(572	)		—			—			(572	)
Net cash (used in) provided by operating activities		(7,080	)		152,145			76,763			(4,514	)		217,314
Investing activities:
Cash paid for capital expenditures		—			(97,186	)		(64,369	)		—			(161,555	)
Cash paid for real estate acquisitions		—			(8,857	)		—			—			(8,857	)
Other		—			(5,759	)		2,422			—			(3,337	)
Net cash used in investing activities		—			(111,802	)		(61,947	)		—			(173,749	)
Financing activities:
Principal payments on long-term debt		(23,246	)		(169	)		(4,345	)		4,514			(23,246	)
Common stock withheld for minimum statutory taxes, net		(2,134	)		—			—			—			(2,134	)
Other		(1,742	)		(1,924	)		(1,506	)		—			(5,172	)
Cash provided by (used in) intercompany activity		34,202			(25,131	)		(9,071	)		—			—
Net provided by (used in) in financing activities		7,080			(27,224	)		(14,922	)		4,514			(30,552	)
Effect of exchange rate changes on cash		—			—			(840	)		—			(840	)
Net increase (decrease) in cash and cash equivalents		—			13,119			(946	)		—			12,173
Cash and cash equivalents at beginning of the period		—			46,860			20,430			—			67,290
Cash and cash equivalents at end of the period	$	—		$	59,979		$	19,484		$	—		$	79,463

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Cash Flows

Six Months Ended June 30, 2017

(In thousands)

	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Operating activities:
Net income (loss)	$	84,411		$	75,376		$	32,630		$	(108,006	)	$	84,411
Adjustments to reconcile net income (loss) to net cash provided by (used in) continuing operating activities:
Equity in earnings of subsidiaries		(108,006	)		—			—			108,006			—
Depreciation and amortization		—			31,955			36,859			—			68,814
Amortization of debt issuance costs		5,053			—			(208	)		—			4,845
Equity-based compensation expense		14,832			—			—			—			14,832
Deferred income taxes		1,610			12,268			3,218			—			17,096
Debt extinguishment costs		810			—			—			—			810
Other		2,692			1,181			2,685			—			6,558
Change in operating assets and liabilities:
Accounts receivable, net		—			(13,423	)		(8,981	)		—			(22,404	)
Other current assets		—			(3,564	)		24,021			—			20,457
Other assets		3,397			1,705			104			(3,397	)		1,809
Accounts payable and other accrued liabilities		—			3,747			(8,640	)		—			(4,893	)
Accrued salaries and benefits		—			(6,591	)		(2,566	)		—			(9,157	)
Other liabilities		—			1,625			3,632			—			5,257
Net cash provided by (used in) continuing operating activities		4,799			104,279			82,754			(3,397	)		188,435
Net cash used in discontinued operating activities		—			(829	)		—			—			(829	)
Net cash provided by (used in) operating activities		4,799			103,450			82,754			(3,397	)		187,606
Investing activities:
Cash paid for capital expenditures		—			(71,274	)		(46,247	)		—			(117,521	)
Cash paid for real estate acquisitions		—			(22,850	)		—			—			(22,850	)
Other		—			(7,543	)		1,605			—			(5,938	)
Net cash used in investing activities		—			(101,667	)		(44,642	)		—			(146,309	)
Financing activities:
Principal payments on long-term debt		(17,275	)		—			(3,397	)		3,397			(17,275	)
Common stock withheld for minimum statutory taxes, net		(3,678	)		—			—			—			(3,678	)
Other		—			(2,270	)		—			—			(2,270	)
Cash provided by (used in) intercompany activity		16,154			32,629			(48,783	)		—			—
Net (used in) provided by in financing activities		(4,799	)		30,359			(52,180	)		3,397			(23,223	)
Effect of exchange rate changes on cash		—			—			4,297			—			4,297
Net decrease in cash and cash equivalents		—			32,142			(9,771	)		—			22,371
Cash and cash equivalents at beginning of the period		—			15,681			41,382			—			57,063
Cash and cash equivalents at end of the period	$	—		$	47,823		$	31,611		$	—		$	79,434

Description of Business and Basis of Presentation - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2018 Facility Bed State
Accounting Policies [Abstract]
Number of facilities \| Facility	585
Number of beds \| Bed	17,900
Number of operating states \| State	40

Revenue - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
Revenue - Additional Information (Detail) - USD ($)	Mar. 31, 2018	Mar. 31, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Cost report receivables			$ 12,200,000		$ 9,000,000
Costs of providing charity care services	$ 1,200,000	$ 1,400,000	2,800,000	$ 3,000,000
Accounting Standards Update 2014-09 [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Cumulative-effect adjustment in retained earnings			$ 0

Revenue - Summary of Impact of Adoption of Accounting Standards (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue before provision for doubtful accounts	$ 765,738	$ 725,643	$ 1,507,979	$ 1,414,984
Provision for doubtful accounts		(9,747)		(19,894)
Revenue	765,738	$ 715,896	1,507,979	$ 1,395,090
Calculated under Revenue Guidance in Effect before Topic 606 [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue before provision for doubtful accounts	775,203		1,525,704
Provision for doubtful accounts	(9,465)		(17,725)
Revenue	$ 765,738		$ 1,507,979

Revenue - Schedule of U.S. Revenue Attributed to Each Category (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Disaggregation of Revenue [Line Items]
Revenue	$ 765,738	$ 715,896	$ 1,507,979	$ 1,395,090
U.S. Facilities [Member]
Disaggregation of Revenue [Line Items]
Revenue	481,470	461,414	943,875	901,637
U.S. Facilities [Member] \| Acute Inpatient Psychiatric Facilities [Member]
Disaggregation of Revenue [Line Items]
Revenue	203,535	193,989	399,426	378,676
U.S. Facilities [Member] \| Specialty Treatment Facilities [Member]
Disaggregation of Revenue [Line Items]
Revenue	192,894	182,748	377,429	357,945
U.S. Facilities [Member] \| Residential Treatment Centers [Member]
Disaggregation of Revenue [Line Items]
Revenue	74,133	73,180	145,690	142,467
U.S. Facilities [Member] \| Outpatient Community-Based Services [Member]
Disaggregation of Revenue [Line Items]
Revenue	$ 10,908	$ 11,497	$ 21,330	$ 22,549

Revenue - Schedule of U.S. Revenue Generated by Each Payor Type (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue before provision for doubtful accounts	$ 765,738	$ 725,643	$ 1,507,979	$ 1,414,984
Provision for doubtful accounts		(9,747)		(19,894)
Revenue	765,738	715,896	1,507,979	1,395,090
U.S. Facilities [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue before provision for doubtful accounts	481,470	471,161	943,875	921,525
Provision for doubtful accounts		(9,747)		(19,888)
Revenue	481,470	461,414	943,875	901,637
U.S. Facilities [Member] \| Commercial [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue before provision for doubtful accounts	147,279	149,493	284,898	288,948
U.S. Facilities [Member] \| Medicare [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue before provision for doubtful accounts	69,508	71,559	136,779	139,399
U.S. Facilities [Member] \| Medicaid [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue before provision for doubtful accounts	225,567	197,279	438,846	388,113
U.S. Facilities [Member] \| Self-Pay [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue before provision for doubtful accounts	33,379	43,561	70,286	87,243
U.S. Facilities [Member] \| Other [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue before provision for doubtful accounts	$ 5,737	$ 9,269	$ 13,066	$ 17,822

Revenue - Schedule of U.K. Revenue Attributed to Each Category (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Disaggregation of Revenue [Line Items]
Revenue	$ 765,738	$ 715,896	$ 1,507,979	$ 1,395,090
U.K. Facilities [Member]
Disaggregation of Revenue [Line Items]
Revenue	284,268	254,482	564,104	493,453
U.K. Facilities [Member] \| Health Care Facilities [Member]
Disaggregation of Revenue [Line Items]
Revenue	159,060	141,187	313,860	273,285
U.K. Facilities [Member] \| Education and Children's Services [Member]
Disaggregation of Revenue [Line Items]
Revenue	49,310	42,199	98,643	81,896
U.K. Facilities [Member] \| Adult Care Facilities [Member]
Disaggregation of Revenue [Line Items]
Revenue	$ 75,898	$ 71,096	$ 151,601	$ 138,272

Revenue - Schedule of U.K. Revenue Generated by Each Payor Type (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue before provision for doubtful accounts	$ 765,738	$ 725,643	$ 1,507,979	$ 1,414,984
Provision for doubtful accounts		(9,747)		(19,894)
Revenue	765,738	715,896	1,507,979	1,395,090
U.K. Facilities [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue before provision for doubtful accounts	284,268	254,482	564,104	493,459
Provision for doubtful accounts				(6)
Revenue	284,268	254,482	564,104	493,453
U.K. Facilities [Member] \| U.K. Public Funded Sources [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue before provision for doubtful accounts	256,881	226,380	510,175	441,845
U.K. Facilities [Member] \| Self-Pay [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue before provision for doubtful accounts	27,272	23,889	52,340	46,090
U.K. Facilities [Member] \| Other [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue before provision for doubtful accounts	$ 115	$ 4,213	$ 1,589	$ 5,524

Revenue - Summary of the Activity in Unearned Revenue (Detail) - U.K. Facilities [Member] - Unearned Revenue [Member] $ in Thousands	6 Months Ended
	Jun. 30, 2018 USD ($)
Disaggregation of Revenue [Line Items]
Beginning Balance	$ 30,812
Payments received	84,541
Revenue recognized	(82,580)
Foreign currency translation loss	(1,340)
Ending Balance	$ 31,433

Earnings Per Share - Computation of Basic and Diluted Earnings Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Numerator:
Net income attributable to Acadia Healthcare Company, Inc.	$ 58,836	$ 49,630	$ 109,655	$ 84,588
Denominator:
Weighted average shares outstanding for basic earnings per share	87,303	86,954	87,205	86,859
Effect of dilutive instruments	164	126	146	138
Shares used in computing diluted earnings per common share	87,467	87,080	87,351	86,997
Earnings per share attributable to Acadia Healthcare Company, Inc. stockholders:
Basic	$ 0.67	$ 0.57	$ 1.26	$ 0.97
Diluted	$ 0.67	$ 0.57	$ 1.26	$ 0.97

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Earnings Per Share - Additional Information (Detail) - shares shares in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Earnings Per Share [Abstract]
Excluded common stock for computation of diluted earnings per share	1.6	1.6	2.0	1.1

Other Intangible Assets - Other Identifiable Intangible Assets and Related Accumulated Amortization (Detail) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets subject to amortization, Gross Carrying Amount	$ 3,247	$ 3,247
Intangible assets not subject to amortization, Gross Carrying Amount	91,566	87,348
Total	94,813	90,595
Intangible assets subject to amortization, Accumulated Amortization	(3,247)	(3,247)
Intangible assets not subject to amortization, Accumulated Amortization	0	0
Total	(3,247)	(3,247)
Contract Intangible Assets [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets subject to amortization, Gross Carrying Amount	2,100	2,100
Intangible assets subject to amortization, Accumulated Amortization	(2,100)	(2,100)
Non-Compete Agreements [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets subject to amortization, Gross Carrying Amount	1,147	1,147
Intangible assets subject to amortization, Accumulated Amortization	(1,147)	(1,147)
Licenses and Accreditations [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets not subject to amortization, Gross Carrying Amount	12,772	12,266
Intangible assets not subject to amortization, Accumulated Amortization	0	0
Trade Names [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets not subject to amortization, Gross Carrying Amount	61,960	60,586
Intangible assets not subject to amortization, Accumulated Amortization	0	0
Certificates of Need [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets not subject to amortization, Gross Carrying Amount	16,834	14,496
Intangible assets not subject to amortization, Accumulated Amortization	$ 0	$ 0

Property and Equipment - Summary of Property and Equipment (Detail) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 3,525,133	$ 3,395,549
Less accumulated depreciation	(421,802)	(347,419)
Property and equipment, net	3,103,331	3,048,130
Land [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	451,264	450,342
Building and Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	2,440,139	2,370,918
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	438,033	400,596
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 195,697	$ 173,693

Long-Term Debt - Components of Long-Term Debt (Detail) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017	Sep. 21, 2015
Debt Instrument [Line Items]
Less: unamortized debt issuance costs, discount and premium	$ (46,022)	$ (50,432)
Long-term debt	3,221,052	3,239,888
Less: current portion	(33,264)	(34,830)
Long-term debt	3,187,788	3,205,058
Amended and Restated Senior Credit Facility [Member] \| Senior Secured Term A Loans [Member]
Debt Instrument [Line Items]
Senior Secured	375,250	380,000
Amended and Restated Senior Credit Facility [Member] \| Senior Secured Term B Loans [Member]
Debt Instrument [Line Items]
Senior Secured	1,379,904	1,398,400
6.125% Senior Notes Due 2021 [Member]
Debt Instrument [Line Items]
Senior Notes	150,000	150,000
5.125% Senior Notes Due 2022 [Member]
Debt Instrument [Line Items]
Senior Notes	300,000	300,000
5.625% Senior Notes Due 2023 [Member]
Debt Instrument [Line Items]
Senior Notes	650,000	650,000	$ 650,000
6.500% Senior Notes Due 2024 [Member]
Debt Instrument [Line Items]
Senior Notes	390,000	390,000
9.0% and 9.5% Revenue Bonds [Member]
Debt Instrument [Line Items]
9.0% and 9.5% Revenue Bonds	$ 21,920	$ 21,920

Long-Term Debt - Components of Long-Term Debt (Parenthetical) (Detail)	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017	Feb. 16, 2016	Sep. 21, 2015	Feb. 11, 2015	Jul. 01, 2014	Mar. 12, 2013
6.125% Senior Notes Due 2021 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	6.125%	6.125%					6.125%
Senior notes maturity year	2021	2021
5.125% Senior Notes Due 2022 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.125%	5.125%				5.125%
Senior notes maturity year	2022	2022
5.625% Senior Notes Due 2023 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.625%	5.625%		5.625%	5.625%
Senior notes maturity year	2023	2023
6.500% Senior Notes Due 2024 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	6.50%	6.50%	6.50%
Senior notes maturity year	2024	2024
9.0% Revenue Bonds [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	9.00%	9.00%
9.5% Revenue Bonds [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	9.50%	9.50%

Long-Term Debt (Amended and Restated Senior Credit Facility) - Additional Information (Detail) - USD ($)											3 Months Ended					6 Months Ended		12 Months Ended
	Apr. 17, 2018	Mar. 29, 2018	Mar. 22, 2018	Mar. 21, 2018	Dec. 29, 2017	May 10, 2017	May 09, 2017	Dec. 15, 2015	Dec. 31, 2012	Apr. 01, 2011	Jun. 30, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Dec. 15, 2014
Debt Instrument [Line Items]
Debt extinguishment costs											$ (810,000)					$ (940,000)	$ (810,000)
Term loan repayments	$ 15,000,000				$ 22,500,000
Consolidated funded debt, unrestricted and unencumbered cash to consolidated EBITDA																			$ 40,000,000
Term Loan A- Facility [Member]
Debt Instrument [Line Items]
Line of credit		$ 400,000,000
Tranche B-1 Repricing Amendment [Member]
Debt Instrument [Line Items]
Term loan repayments					7,700,000
Tranche B-2 Repricing Amendment [Member]
Debt Instrument [Line Items]
Term loan repayments					$ 14,800,000
Tranche B-3 Facility [Member]
Debt Instrument [Line Items]
Term loan repayments	5,100,000
Tranche B-4 Facilities [Member]
Debt Instrument [Line Items]
Term loan repayments	$ 9,900,000
Eurodollar [Member]
Debt Instrument [Line Items]
Interest on borrowings																2.50%
Base Rate Loans [Member]
Debt Instrument [Line Items]
Interest on borrowings																1.50%
Amended and Restated Senior Credit Facility [Member]
Debt Instrument [Line Items]
Date entered into an agreement									Dec. 31, 2012	Apr. 01, 2011
Amount available under revolving line of credit																$ 495,000,000
Debt instrument maturity date								Nov. 30, 2021										Feb. 11, 2022
Term loan repayments															$ 1,200,000
Amended and Restated Senior Credit Facility [Member] \| September 30, 2018 to December 31, 2019 [Member]
Debt Instrument [Line Items]
Term loan principal repayments								$ 4,800,000
Term loan repayments														$ 1,200,000
Amended and Restated Senior Credit Facility [Member] \| March 31, 2020 to December 31, 2020 [Member]
Debt Instrument [Line Items]
Term loan principal repayments								7,100,000
Term loan repayments												$ 1,200,000
Amended and Restated Senior Credit Facility [Member] \| March 31, 2021 to September 30, 2021 [Member]
Debt Instrument [Line Items]
Term loan principal repayments								$ 9,500,000
Amended and Restated Senior Credit Facility [Member] \| September 30, 2015 to December 31, 2015 [Member]
Debt Instrument [Line Items]
Term loan repayments													$ 1,200,000
Amended and Restated Senior Credit Facility [Member] \| Standby Letters of Credit [Member]
Debt Instrument [Line Items]
Standby letters of credit outstanding																$ 5,000,000
Amended and Restated Senior Credit Facility [Member] \| TLB Facility Due on February 16, 2023 [Member]
Debt Instrument [Line Items]
Term loan repayments															$ 2,300,000
Amended and Restated Senior Credit Facility [Member] \| TLB Facility Due on February 16, 2023 [Member] \| September 30, 2018 to December 31, 2019 [Member]
Debt Instrument [Line Items]
Term loan repayments														$ 2,300,000
Amended and Restated Senior Credit Facility [Member] \| TLB Facility Due on February 16, 2023 [Member] \| March 31, 2020 to December 31, 2020 [Member]
Debt Instrument [Line Items]
Term loan repayments												$ 2,300,000
Amended and Restated Senior Credit Facility [Member] \| TLB Facility Due on February 16, 2023 [Member] \| September 30, 2015 to December 31, 2015 [Member]
Debt Instrument [Line Items]
Term loan repayments													$ 2,300,000
Amended and Restated Senior Credit Facility [Member] \| Third Repricing Amendment [Member]
Debt Instrument [Line Items]
Debt extinguishment costs						$ 800,000
Amended and Restated Senior Credit Facility [Member] \| Repricing Facilities Amendments [Member]
Debt Instrument [Line Items]
Debt extinguishment costs			$ 900,000
Revolving credit facility applicable rate		0.25%
Amended and Restated Senior Credit Facility [Member] \| Repricing Facilities Amendments [Member] \| Senior Secured Revolving Line of Credit [Member]
Debt Instrument [Line Items]
Line of credit		$ 500,000,000
Amended and Restated Senior Credit Facility [Member] \| Repricing Facilities Amendments [Member] \| Term Loan A- Facility [Member]
Debt Instrument [Line Items]
Line of credit		$ 380,000,000
Amended and Restated Senior Credit Facility [Member] \| Eurodollar [Member]
Debt Instrument [Line Items]
Basis spread on variable rate																1.00%
Amended and Restated Senior Credit Facility [Member] \| Eurodollar [Member] \| Third Repricing Amendment [Member]
Debt Instrument [Line Items]
Interest on borrowings						2.75%	3.00%
Amended and Restated Senior Credit Facility [Member] \| Eurodollar [Member] \| Repricing Facilities Amendments [Member]
Debt Instrument [Line Items]
Interest on borrowings			2.50%	2.75%
Amended and Restated Senior Credit Facility [Member] \| Base Rate Loans [Member]
Debt Instrument [Line Items]
Basis spread on variable rate																0.50%
Amended and Restated Senior Credit Facility [Member] \| Base Rate Loans [Member] \| Third Repricing Amendment [Member]
Debt Instrument [Line Items]
Interest on borrowings						1.75%	2.00%
Amended and Restated Senior Credit Facility [Member] \| Base Rate Loans [Member] \| Repricing Facilities Amendments [Member]
Debt Instrument [Line Items]
Interest on borrowings			1.50%	1.75%
Amended and Restated Senior Credit Facility [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Interest on borrowings																2.50%

Long-Term Debt (6.125% Senior Notes due 2021) - Additional Information (Detail) - 6.125% Senior Notes Due 2021 [Member] - USD ($)		6 Months Ended
	Mar. 12, 2013	Jun. 30, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Issued Senior Notes	$ 150,000,000
Debt instrument interest rate	6.125%	6.125%	6.125%
Debt instrument maturity date	Mar. 15, 2021
Interest on the notes		Payable semi-annually in arrears on March 15 and September 15 of each year.

Long-Term Debt (5.125% Senior Notes due 2022) - Additional Information (Detail) - 5.125% Senior Notes Due 2022 [Member] - USD ($)		6 Months Ended
	Jul. 01, 2014	Jun. 30, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Issued Senior Notes	$ 300,000,000
Debt instrument interest rate	5.125%	5.125%	5.125%
Debt instrument maturity date	Jul. 01, 2022
Interest on the notes		Payable semi-annually in arrears on January 1 and July 1 of each year.

Long-Term Debt (5.625% Senior Notes due 2023) - Additional Information (Detail) - 5.625% Senior Notes Due 2023 [Member] - USD ($)	6 Months Ended
	Jun. 30, 2018	Dec. 31, 2017	Sep. 21, 2015	Feb. 11, 2015
Debt Instrument [Line Items]
Issued Senior Notes			$ 275,000,000	$ 375,000,000
Debt instrument interest rate	5.625%	5.625%	5.625%	5.625%
Senior Notes	$ 650,000,000	$ 650,000,000	$ 650,000,000
Debt instrument maturity date	Feb. 15, 2023
Interest on the notes	Payable semi-annually in arrears on February 15 and August 15 of each year.

Long-Term Debt (6.500% Senior Notes due 2024) - Additional Information (Detail) - 6.500% Senior Notes Due 2024 [Member] - USD ($)		6 Months Ended
	Feb. 16, 2016	Jun. 30, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Issued Senior Notes	$ 390,000,000
Debt instrument interest rate	6.50%	6.50%	6.50%
Debt instrument maturity date	Mar. 01, 2024
Interest on the notes		Payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2016.

Long-Term Debt (9.0% and 9.5% Revenue Bonds) - Additional Information (Detail) - USD ($) $ in Thousands	Nov. 11, 2012	Jun. 30, 2018	Dec. 31, 2017
9.0% and 9.5% Revenue Bonds [Member]
Debt Instrument [Line Items]
9.0% and 9.5% Revenue Bonds		$ 21,920	$ 21,920
9.0% and 9.5% Revenue Bonds [Member] \| Park Royal [Member]
Debt Instrument [Line Items]
9.0% and 9.5% Revenue Bonds	$ 23,000
Debt service reserve fund within other assets		$ 2,300	$ 2,300
Debt instrument premium	2,600
9.0% and 9.5% Revenue Bonds [Member] \| Fair Value [Member] \| Park Royal [Member]
Debt Instrument [Line Items]
9.0% and 9.5% Revenue Bonds	25,600
9.0% Revenue Bonds [Member]
Debt Instrument [Line Items]
Debt instrument interest rate		9.00%	9.00%
9.0% Revenue Bonds [Member] \| Park Royal [Member]
Debt Instrument [Line Items]
9.0% and 9.5% Revenue Bonds	$ 7,500
Debt instrument interest rate	9.00%
Debt instrument maturity date	Dec. 01, 2030
9.5% Revenue Bonds [Member]
Debt Instrument [Line Items]
Debt instrument interest rate		9.50%	9.50%
9.5% Revenue Bonds [Member] \| Park Royal [Member]
Debt Instrument [Line Items]
9.0% and 9.5% Revenue Bonds	$ 15,500
Debt instrument interest rate	9.50%
Debt instrument maturity date	Dec. 01, 2040

Equity-Based Compensation - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Authorized common stock	8,200,000		8,200,000
Equity incentive plan available for future grant	3,221,669		3,221,669
Annual increments in employee grants			25.00%
Stock options, contractual term			10 years
Equity-based compensation expense	$ 7,129,000	$ 7,436,000	$ 14,048,000	$ 14,832,000
Unrecognized compensation expense related to unvested options			$ 56,500,000
Vesting period			1 year 3 months 18 days
Warrant outstanding	0		$ 0
Deferred income tax benefit			(3,978,000)	17,096,000
Stock Compensation Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Deferred income tax benefit	$ 1,900,000	$ 2,800,000	$ 3,800,000	$ 5,700,000
Restricted Stock Award [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			3 years
Restricted Stock Award [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			4 years
Restricted Stock Units [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			2 years
Number of shares issuable at the end of the vesting period, percentage			0.00%
Restricted Stock Units [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			3 years
Number of shares issuable at the end of the vesting period, percentage			200.00%

Equity-Based Compensation - Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Options outstanding, Beginning balance	974,566	1,000,946
Options granted	353,800	259,300
Options exercised	(8,689)	(87,367)
Options cancelled	(86,112)	(198,313)
Options outstanding, Ending balance	1,233,565	974,566	1,000,946
Options exercisable, Ending balance	541,589	405,634
Options outstanding, Weighted Average Exercise Price, Beginning balance	$ 47.89	$ 49.42
Options granted, Weighted Average Exercise Price	37.36	42.25
Options exercised, Weighted Average Exercise Price	25.87	25.92
Options cancelled, Weighted Average Exercise Price	51.97	54.71
Options outstanding, Weighted Average Exercise Price, Ending balance	44.70	47.89	$ 49.42
Options exercisable, Weighted Average Exercise Price, Ending balance	$ 44.53	$ 41.20
Options outstanding, Weighted Average Remaining Contractual Term	7 years 5 months 1 day	7 years 5 months 15 days	7 years 9 months 18 days
Options granted, Weighted Average Remaining Contractual Term	7 years 10 months 6 days	9 years 3 months 18 days
Options exercisable, Weighted Average Remaining Contractual Term, Ending balance	6 years 1 month 9 days	6 years 18 days
Options outstanding, Aggregate Intrinsic Value	$ 2,764	$ 3,802	$ 8,166
Options granted, Aggregate Intrinsic Value	137	205
Options exercised, Aggregate Intrinsic Value	134	1,636
Options cancelled, Aggregate Intrinsic Value	0	0
Options exercisable, Aggregate Intrinsic Value, Ending balance	$ 2,494	$ 3,549

Equity-Based Compensation - Schedule of Stock Options Valuation Assumptions (Detail) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Weighted average grant-date fair value of options	$ 13.61	$ 14.39
Risk-free interest rate	2.20%	2.00%
Expected volatility	38.00%	33.00%
Expected life (in years)	5 years	5 years 6 months

Equity-Based Compensation - Restricted Stock Activity (Detail) - Restricted Stock Award [Member] - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested, Number of Shares/Units, Beginning balance	809,868	844,419
Granted, Number of Shares	441,837	404,224
Cancelled, Number of Shares	(58,217)	(145,981)
Vested, Number of Shares	(245,814)	(292,794)
Unvested, Number of Shares/Units, Ending balance	947,674	809,868
Unvested, Weighted Average Grant-Date Fair Value, Beginning balance	$ 50.19	$ 55.76
Granted, Weighted Average Grant-Date Fair Value	36.51	42.38
Cancelled, Weighted Average Grant-Date Fair Value	49.25	55.03
Vested, Weighted Average Grant-Date Fair Value	53.44	53.07
Unvested, Weighted Average Grant-Date Fair Value, Ending balance	$ 43.03	$ 50.19

Equity-Based Compensation - Restricted Stock Unit Activity (Detail) - Restricted Stock Units [Member] - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested, Number of Shares/Units, Beginning balance	360,909	273,599
Granted, Number of Units	285,358	219,840
Cancelled, Number of Units	(89,173)
Vested, Number of Units	(72,983)	(132,530)
Unvested, Number of Shares/Units, Ending balance	484,111	360,909
Unvested, Weighted Average Grant-Date Fair Value, Beginning balance	$ 50.04	$ 59.68
Granted, Weighted Average Grant-Date Fair Value	42.26	43.23
Cancelled, Weighted Average Grant-Date Fair Value	55.44
Vested, Weighted Average Grant-Date Fair Value	49.64	58.67
Unvested, Weighted Average Grant-Date Fair Value, Ending balance	$ 44.52	$ 50.04

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Income Tax Examination [Line Items]
Effective tax rates	15.00%	25.00%	6.50%	26.40%
Discrete tax benefit recorded	$ (10,368)	$ (16,578)	$ (7,582)	$ (30,289)
Increase in income tax provision due to adoption of ASU 2016-09			$ 1,600	$ 1,700
Percentage increase in income tax provision due to adoption of ASU 2016-09			1.40%	1.50%
U.S. federal statutory rate on income before income taxes			21.00%		35.00%
Transition tax on certain repatriated earnings of foreign subsidiaries payable period			8 years
Provisional tax amount			$ 19,300
One-time transition tax liability, foreign earnings	0		0
Deferred tax balance	$ 19,300		19,300
Provisional amount of transition tax liability, foreign subsidiaries			0
Foreign dividends			10,900
Change in Accounting Method Accounted for as Change in Estimate [Member]
Income Tax Examination [Line Items]
Discrete tax benefit recorded			$ 10,500

Derivatives - Additional Information (Detail)	1 Months Ended
Derivatives - Additional Information (Detail)	May 31, 2016 USD ($)	May 31, 2016 GBP (£)	Jun. 30, 2018 USD ($)	May 31, 2016 GBP (£)
Derivative [Line Items]
Cross currency swap assets			$ 25,000,000
Cross Currency Swap Assets [Member]
Derivative [Line Items]
Notional amount	$ 650,000,000			£ 449,300,000
Cross currency swap agreement cash flow due to interest payment	$ 35,800,000	£ 24,700,000
Derivative exchange rate	1.45			1.45

Fair Value Measurements - Carrying Amounts and Fair Values of Company's Amended and Restated Senior Credit Facilities and Contingent Consideration Liabilities (Detail) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative instrument assets	$ 24,989	$ 12,997
Carrying Amount [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative instrument assets	24,989	12,997
Carrying Amount [Member] \| Amended and Restated Senior Credit Facility [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Secured	1,728,688	1,749,185
Carrying Amount [Member] \| 6.125% Senior Notes Due 2021 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	148,373	148,098
Carrying Amount [Member] \| 5.125% Senior Notes Due 2022 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	296,555	296,174
Carrying Amount [Member] \| 5.625% Senior Notes Due 2023 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	642,580	641,891
Carrying Amount [Member] \| 6.500% Senior Notes due 2024 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	382,769	382,251
Carrying Amount [Member] \| 9.0% and 9.5% Revenue Bonds [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
9.0% and 9.5% Revenue Bonds	22,087	22,289
Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative instrument assets	24,989	12,997
Fair Value [Member] \| Amended and Restated Senior Credit Facility [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Amended and Restated Senior Credit Facility	1,728,688	1,749,185
Fair Value [Member] \| 6.125% Senior Notes Due 2021 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	149,857	150,134
Fair Value [Member] \| 5.125% Senior Notes Due 2022 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	295,814	296,914
Fair Value [Member] \| 5.625% Senior Notes Due 2023 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	647,399	651,519
Fair Value [Member] \| 6.500% Senior Notes due 2024 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	392,338	397,541
Fair Value [Member] \| 9.0% and 9.5% Revenue Bonds [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
9.0% and 9.5% Revenue Bonds	$ 22,087	$ 22,289

Fair Value Measurements - Additional Information (Detail)	Jun. 30, 2018	Dec. 31, 2017	Feb. 16, 2016	Sep. 21, 2015	Feb. 11, 2015	Jul. 01, 2014	Mar. 12, 2013
6.125% Senior Notes Due 2021 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	6.125%	6.125%					6.125%
5.125% Senior Notes Due 2022 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.125%	5.125%				5.125%
5.625% Senior Notes Due 2023 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.625%	5.625%		5.625%	5.625%
6.500% Senior Notes Due 2024 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	6.50%	6.50%	6.50%
9.0% Revenue Bonds [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	9.00%	9.00%
9.5% Revenue Bonds [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	9.50%	9.50%

Commitments and Contingencies - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2018 USD ($)
Loss Contingencies [Line Items]
Maximum professional liability aggregate policy limit	$ 75,000,000
Maximum [Member]
Loss Contingencies [Line Items]
Maximum self insured professional liability limit per claim	3,000,000
Minimum [Member]
Loss Contingencies [Line Items]
Maximum professional liability retention limit	$ 3,000,000

Noncontrolling Interests - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2018 Facility
Noncontrolling Interest [Line Items]
Number of facilities operated by non-wholly owned subsidiaries	4
Minimum [Member]
Noncontrolling Interest [Line Items]
Equity ownership interests percentage in the facility	60.00%
Maximum [Member]
Noncontrolling Interest [Line Items]
Equity ownership interests percentage in the facility	80.00%

Noncontrolling Interests - Summary of Redeemable Noncontrolling Interests (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2018 USD ($)
Noncontrolling Interest [Abstract]
Beginning Balance	$ 22,417
Contribution of redeemable noncontrolling interests	6,265
Net income attributable to noncontrolling interests	109
Ending Balance	$ 28,791

Other Current Assets - Other Current Assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Prepaid expenses	$ 28,379	$ 27,320
Other receivables	29,791	30,455
Workers’ compensation deposits – current portion	10,000	10,000
Inventory	4,733	4,787
Income taxes receivable	3,885	15,056
Insurance receivable-current portion	1,688	17,588
Other	2,027	2,129
Other current assets	$ 80,503	$ 107,335

Other Accrued Liabilities - Summary of Other Accrued Liabilities (Detail) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Accounts Payable And Accrued Liabilities Current [Abstract]
Accrued interest	$ 33,156	$ 36,370
Unearned income	32,362	31,342
Accrued expenses	32,113	37,268
Income taxes payable	8,966	1,012
Insurance liability – current portion	6,888	22,788
Accrued property taxes	4,530	3,945
Other	9,771	8,488
Other accrued liabilities	$ 127,786	$ 141,213

Segment Information - Additional Information (Detail)	6 Months Ended
Segment Information - Additional Information (Detail)	Jun. 30, 2018 Facility Bed State
Segment Reporting Information [Line Items]
Number of facilities \| Facility	585
Number of beds \| Bed	17,900
Number of operating states \| State	40
U.S. Facilities [Member]
Segment Reporting Information [Line Items]
Number of facilities \| Facility	213
Number of beds \| Bed	9,100
Number of operating states \| State	40
U.K. Facilities [Member]
Segment Reporting Information [Line Items]
Number of facilities \| Facility	372
Number of beds \| Bed	8,800

Segment Information - Summary of Reconciliation of Segment EBITDA to Income from Continuing Operations (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Segment Reporting Information [Line Items]
Revenue	$ 765,738	$ 715,896	$ 1,507,979	$ 1,395,090
Segment EBITDA	165,014	162,220	310,745	298,589
Equity-based compensation expense	(7,129)	(7,436)	(14,048)	(14,832)
Transaction-related expenses	(2,887)	(9,052)	(7,655)	(13,171)
Debt extinguishment costs		(810)	(940)	(810)
Interest expense, net	(45,812)	(43,505)	(91,055)	(86,262)
Depreciation and amortization	(39,928)	(35,201)	(79,701)	(68,814)
Income before income taxes	69,258	66,216	117,346	114,700
U.S. Facilities [Member] \| Operating Segment [Member]
Segment Reporting Information [Line Items]
Revenue	481,470	461,414	943,875	901,637
Segment EBITDA	130,002	128,361	247,126	240,506
U.K. Facilities [Member] \| Operating Segment [Member]
Segment Reporting Information [Line Items]
Revenue	284,268	254,482	564,104	493,453
Segment EBITDA	54,194	52,090	105,346	96,276
Corporate and Other [Member] \| Corporate Reconciling Items and Eliminations [Member]
Segment Reporting Information [Line Items]
Segment EBITDA	$ (19,182)	$ (18,231)	$ (41,727)	$ (38,193)

Segment Information - Summary of Financial Information by Operating Segment, Goodwill (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2018 USD ($)
Goodwill:
Beginning balance	$ 2,751,174
Increase from contribution of redeemable noncontrolling interests	2,244
Foreign currency translation loss	(14,877)
Prior year purchase price adjustments	762
Ending balance	2,739,303
U.S. Facilities [Member] \| Operating Segment [Member]
Goodwill:
Beginning balance	2,042,592
Increase from contribution of redeemable noncontrolling interests	2,244
Ending balance	2,044,836
U.K. Facilities [Member] \| Operating Segment [Member]
Goodwill:
Beginning balance	708,582
Foreign currency translation loss	(14,877)
Prior year purchase price adjustments	762
Ending balance	$ 694,467

Segment Information - Summary of Financial Information by Operating Segment, Assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Assets:
Assets	$ 6,503,147	$ 6,424,502
U.S. Facilities [Member] \| Operating Segment [Member]
Assets:
Assets	3,694,600	3,567,126
U.K. Facilities [Member] \| Operating Segment [Member]
Assets:
Assets	2,599,911	2,647,150
Corporate and Other [Member] \| Corporate Reconciling Items and Eliminations [Member]
Assets:
Assets	$ 208,636	$ 210,226

Segment Information - Summary of Financial Information by Operating Segment, Assets (Parenthetical) (Detail) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Segment Reporting, Asset Reconciling Item [Line Items]
Property and equipment, net	$ 3,103,331	$ 3,048,130
Operating Segment [Member] \| U.S. Facilities [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Property and equipment, net	1,300,000	1,200,000
Operating Segment [Member] \| U.K. Facilities [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Property and equipment, net	1,800,000	1,800,000
Corporate Reconciling Items and Eliminations [Member] \| Corporate and Other [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Property and equipment, net	$ 50,400	$ 49,200

Accumulated Other Comprehensive Loss - Components Of Accumulated Other Comprehensive Loss (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance			$ 2,572,871
Foreign currency translation (loss) gain	$ (143,599)	$ 92,076	(50,819)	$ 119,122
Gain on derivative instruments, net of tax of $3.2 million	29,107	$ (9,084)	9,054	$ (14,952)
Balance	2,653,301		2,653,301
Foreign Currency Translation Adjustments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance			(376,740)
Foreign currency translation (loss) gain			(50,916)
Balance	(427,656)		(427,656)
Change in Fair Value of Derivative Instruments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance			7,167
Gain on derivative instruments, net of tax of $3.2 million			9,054
Balance	16,221		16,221
Pension Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance			(4,545)
Foreign currency translation (loss) gain			97
Balance	(4,448)		(4,448)
Other Comprehensive Loss [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance			(374,118)
Balance	$ (415,883)		$ (415,883)

Accumulated Other Comprehensive Loss - Components Of Accumulated Other Comprehensive Loss (Parenthetical) (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Accumulated Other Comprehensive Income Loss Net Of Tax [Abstract]
Gain (Loss) on derivative instruments, tax	$ 10.5	$ (6.5)	$ 3.2	$ (12.1)

Financial Information for the Company and Its Subsidiaries - Additional Information (Detail)	Jun. 30, 2018	Dec. 31, 2017	Feb. 16, 2016	Sep. 21, 2015	Feb. 11, 2015	Jul. 01, 2014	Mar. 12, 2013
6.125% Senior Notes Due 2021 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	6.125%	6.125%					6.125%
5.125% Senior Notes Due 2022 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	5.125%	5.125%				5.125%
5.625% Senior Notes Due 2023 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	5.625%	5.625%		5.625%	5.625%
6.500% Senior Notes Due 2024 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	6.50%	6.50%	6.50%

Financial Information for the Company and Its Subsidiaries - Summary of Condensed Consolidating Balance Sheets (Detail) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017	Jun. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 79,463	$ 67,290	$ 79,434	$ 57,063
Accounts receivable, net	329,256	296,925
Other current assets	80,503	107,335
Total current assets	489,222	471,550
Property and equipment, net	3,103,331	3,048,130
Goodwill	2,739,303	2,751,174
Intangible assets, net	91,566	87,348
Deferred tax assets	3,664	3,731
Derivative instruments assets	24,989	12,997
Other assets	51,072	49,572
Total assets	6,503,147	6,424,502
Current liabilities:
Current portion of long-term debt	33,264	34,830
Accounts payable	130,228	102,299
Accrued salaries and benefits	102,840	99,047
Other accrued liabilities	127,786	141,213
Total current liabilities	394,118	377,389
Long-term debt	3,187,788	3,205,058
Deferred tax liabilities	78,340	80,333
Other liabilities	160,809	166,434
Total liabilities	3,821,055	3,829,214
Redeemable noncontrolling interests	28,791	22,417
Total equity	2,653,301	2,572,871
Total liabilities and equity	6,503,147	6,424,502
Consolidating Adjustments [Member]
Current assets:
Deferred tax assets	(931)	(2,370)
Investment in subsidiaries	(5,515,341)	(5,429,386)
Other assets	(340,997)	(379,008)
Total assets	(5,857,269)	(5,810,764)
Current liabilities:
Long-term debt	(340,997)	(379,008)
Deferred tax liabilities	(931)	(2,370)
Total liabilities	(341,928)	(381,378)
Total equity	(5,515,341)	(5,429,386)
Total liabilities and equity	(5,857,269)	(5,810,764)
Parent [Member]
Current assets:
Deferred tax assets	931	2,370
Derivative instruments assets	24,989	12,997
Investment in subsidiaries	5,515,341	5,429,386
Other assets	343,990	381,913
Total assets	5,885,251	5,826,666
Current liabilities:
Current portion of long-term debt	32,984	34,550
Other accrued liabilities	32,985	36,196
Total current liabilities	65,969	70,746
Long-term debt	3,165,981	3,183,049
Total liabilities	3,231,950	3,253,795
Total equity	2,653,301	2,572,871
Total liabilities and equity	5,885,251	5,826,666
Combined Subsidiary Guarantors [Member]
Current assets:
Cash and cash equivalents	59,979	46,860	47,823	15,681
Accounts receivable, net	253,954	230,890
Other current assets	56,961	85,746
Total current assets	370,894	363,496
Property and equipment, net	1,161,630	1,086,802
Goodwill	1,936,056	1,936,057
Intangible assets, net	58,295	57,628
Other assets	41,952	38,860
Total assets	3,568,827	3,482,843
Current liabilities:
Accounts payable	86,317	70,767
Accrued salaries and benefits	73,543	69,057
Other accrued liabilities	31,526	27,676
Total current liabilities	191,386	167,500
Deferred tax liabilities	25,311	27,975
Other liabilities	104,283	103,112
Total liabilities	320,980	298,587
Total equity	3,247,847	3,184,256
Total liabilities and equity	3,568,827	3,482,843
Combined Non-Guarantors [Member]
Current assets:
Cash and cash equivalents	19,484	20,430	$ 31,611	$ 41,382
Accounts receivable, net	75,302	66,035
Other current assets	23,542	21,589
Total current assets	118,328	108,054
Property and equipment, net	1,941,701	1,961,328
Goodwill	803,247	815,117
Intangible assets, net	33,271	29,720
Deferred tax assets	3,664	3,731
Other assets	6,127	7,807
Total assets	2,906,338	2,925,757
Current liabilities:
Current portion of long-term debt	280	280
Accounts payable	43,911	31,532
Accrued salaries and benefits	29,297	29,990
Other accrued liabilities	63,275	77,341
Total current liabilities	136,763	139,143
Long-term debt	362,804	401,017
Deferred tax liabilities	53,960	54,728
Other liabilities	56,526	63,322
Total liabilities	610,053	658,210
Redeemable noncontrolling interests	28,791	22,417
Total equity	2,267,494	2,245,130
Total liabilities and equity	$ 2,906,338	$ 2,925,757

Financial Information for the Company and Its Subsidiaries - Summary of Condensed Consolidating Statement of Comprehensive Income (Loss) (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Condensed Financial Statements, Captions [Line Items]
Revenue before provision for doubtful accounts	$ 765,738	$ 725,643	$ 1,507,979	$ 1,414,984
Provision for doubtful accounts		(9,747)		(19,894)
Revenue	765,738	715,896	1,507,979	1,395,090
Salaries, wages and benefits	416,741	383,595	828,269	760,016
Professional fees	53,461	46,321	107,479	89,730
Supplies	30,133	28,639	59,497	56,348
Rents and leases	20,236	19,435	40,524	38,406
Other operating expenses	87,282	83,122	175,513	166,833
Depreciation and amortization	39,928	35,201	79,701	68,814
Interest expense, net	45,812	43,505	91,055	86,262
Debt extinguishment costs		810	940	810
Transaction-related expenses	2,887	9,052	7,655	13,171
Total expenses	696,480	649,680	1,390,633	1,280,390
(Loss) income before income taxes	69,258	66,216	117,346	114,700
(Benefit from) provision for income taxes	10,368	16,578	7,582	30,289
Net income	58,890	49,638	109,764	84,411
Net gain (loss) attributable to noncontrolling interests	(54)	(8)	(109)	177
Net income attributable to Acadia Healthcare Company, Inc.	58,836	49,630	109,655	84,588
Other comprehensive (loss) income:
Foreign currency translation (loss) gain	(143,599)	92,076	(50,819)	119,122
Gain on derivative instruments, net of tax of $3.2 million	29,107	(9,084)	9,054	(14,952)
Other comprehensive (loss) income	(114,492)	82,992	(41,765)	104,170
Comprehensive (loss) income attributable to Acadia Healthcare Company, Inc.	(55,656)	132,622	67,890	188,758
Consolidating Adjustments [Member]
Condensed Financial Statements, Captions [Line Items]
Equity in earnings of subsidiaries	(75,752)	(61,453)	(143,350)	(108,006)
Net income	(75,752)	(61,453)	(143,350)	(108,006)
Net income attributable to Acadia Healthcare Company, Inc.	(75,752)	(61,453)	(143,350)	(108,006)
Other comprehensive (loss) income:
Comprehensive (loss) income attributable to Acadia Healthcare Company, Inc.	(75,752)	(61,453)	(143,350)	(108,006)
Parent [Member]
Condensed Financial Statements, Captions [Line Items]
Salaries, wages and benefits	7,129	7,436	14,048	14,832
Interest expense, net	15,465	15,091	30,082	30,459
Debt extinguishment costs		810	940	810
Total expenses	22,594	23,337	45,070	46,101
(Loss) income before income taxes	(22,594)	(23,337)	(45,070)	(46,101)
Equity in earnings of subsidiaries	75,752	61,453	143,350	108,006
(Benefit from) provision for income taxes	(5,732)	(11,522)	(11,484)	(22,506)
Net income	58,890	49,638	109,764	84,411
Net income attributable to Acadia Healthcare Company, Inc.	58,890	49,638	109,764	84,411
Other comprehensive (loss) income:
Gain on derivative instruments, net of tax of $3.2 million	29,107	(9,084)	9,054	(14,952)
Other comprehensive (loss) income	29,107	(9,084)	9,054	(14,952)
Comprehensive (loss) income attributable to Acadia Healthcare Company, Inc.	87,997	40,554	118,818	69,459
Combined Subsidiary Guarantors [Member]
Condensed Financial Statements, Captions [Line Items]
Revenue before provision for doubtful accounts		444,718		871,514
Provision for doubtful accounts		(8,483)		(17,697)
Revenue	453,782	436,235	889,407	853,817
Salaries, wages and benefits	239,999	225,775	479,051	450,205
Professional fees	24,677	23,337	48,948	45,411
Supplies	19,292	19,050	38,004	37,659
Rents and leases	8,311	8,501	16,550	17,012
Other operating expenses	55,258	54,488	111,428	109,519
Depreciation and amortization	18,611	16,404	36,783	31,955
Interest expense, net	23,602	19,265	47,186	37,750
Transaction-related expenses	2,671	2,570	6,680	4,008
Total expenses	392,421	369,390	784,630	733,519
(Loss) income before income taxes	61,361	66,845	104,777	120,298
(Benefit from) provision for income taxes	11,442	23,852	11,319	44,922
Net income	49,919	42,993	93,458	75,376
Net income attributable to Acadia Healthcare Company, Inc.	49,919	42,993	93,458	75,376
Other comprehensive (loss) income:
Comprehensive (loss) income attributable to Acadia Healthcare Company, Inc.	49,919	42,993	93,458	75,376
Combined Non-Guarantors [Member]
Condensed Financial Statements, Captions [Line Items]
Revenue before provision for doubtful accounts		280,925		543,470
Provision for doubtful accounts		(1,264)		(2,197)
Revenue	311,956	279,661	618,572	541,273
Salaries, wages and benefits	169,613	150,384	335,170	294,979
Professional fees	28,784	22,984	58,531	44,319
Supplies	10,841	9,589	21,493	18,689
Rents and leases	11,925	10,934	23,974	21,394
Other operating expenses	32,024	28,634	64,085	57,314
Depreciation and amortization	21,317	18,797	42,918	36,859
Interest expense, net	6,745	9,149	13,787	18,053
Transaction-related expenses	216	6,482	975	9,163
Total expenses	281,465	256,953	560,933	500,770
(Loss) income before income taxes	30,491	22,708	57,639	40,503
(Benefit from) provision for income taxes	4,658	4,248	7,747	7,873
Net income	25,833	18,460	49,892	32,630
Net gain (loss) attributable to noncontrolling interests	(54)	(8)	(109)	177
Net income attributable to Acadia Healthcare Company, Inc.	25,779	18,452	49,783	32,807
Other comprehensive (loss) income:
Foreign currency translation (loss) gain	(143,599)	92,076	(50,819)	119,122
Other comprehensive (loss) income	(143,599)	92,076	(50,819)	119,122
Comprehensive (loss) income attributable to Acadia Healthcare Company, Inc.	$ (117,820)	$ 110,528	$ (1,036)	$ 151,929

Financial Information for the Company and Its Subsidiaries - Summary of Condensed Consolidating Statement of Cash Flows (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Operating activities:
Net income	$ 58,890	$ 49,638	$ 109,764	$ 84,411
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Depreciation and amortization	39,928	35,201	79,701	68,814
Amortization of debt issuance costs			5,124	4,845
Equity-based compensation expense	7,129	7,436	14,048	14,832
Deferred income taxes			(3,978)	17,096
Debt extinguishment costs		810	940	810
Other			1,040	6,558
Change in operating assets and liabilities:
Accounts receivable, net			(26,104)	(22,404)
Other current assets			9,953	20,457
Other assets			2,761	1,809
Accounts payable and other accrued liabilities			21,066	(4,893)
Accrued salaries and benefits			4,364	(9,157)
Other liabilities			(793)	5,257
Net cash provided by continuing operating activities			217,886	188,435
Net cash used in discontinued operating activities			(572)	(829)
Net cash provided by operating activities			217,314	187,606
Investing activities:
Cash paid for capital expenditures			(161,555)	(117,521)
Cash paid for real estate acquisitions			(8,857)	(22,850)
Other			(3,337)	(5,938)
Net cash used in investing activities			(173,749)	(146,309)
Financing activities:
Principal payments on long-term debt			(23,246)	(17,275)
Common stock withheld for minimum statutory taxes, net			(2,134)	(3,678)
Other			(5,172)	(2,270)
Net cash used in financing activities			(30,552)	(23,223)
Effect of exchange rate changes on cash			(840)	4,297
Net increase in cash and cash equivalents			12,173	22,371
Cash and cash equivalents at beginning of the period			67,290	57,063
Cash and cash equivalents at end of the period	79,463	79,434	79,463	79,434
Consolidating Adjustments [Member]
Operating activities:
Net income	(75,752)	(61,453)	(143,350)	(108,006)
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Equity in earnings of subsidiaries	75,752	61,453	143,350	108,006
Change in operating assets and liabilities:
Other assets			(4,514)	(3,397)
Net cash provided by continuing operating activities			(4,514)	(3,397)
Net cash provided by operating activities			(4,514)	(3,397)
Financing activities:
Principal payments on long-term debt			4,514	3,397
Net cash used in financing activities			4,514	3,397
Parent [Member]
Operating activities:
Net income	58,890	49,638	109,764	84,411
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Equity in earnings of subsidiaries	(75,752)	(61,453)	(143,350)	(108,006)
Amortization of debt issuance costs			5,326	5,053
Equity-based compensation expense			14,048	14,832
Deferred income taxes			1,438	1,610
Debt extinguishment costs		810	940	810
Other			240	2,692
Change in operating assets and liabilities:
Other assets			4,514	3,397
Net cash provided by continuing operating activities			(7,080)	4,799
Net cash provided by operating activities			(7,080)	4,799
Financing activities:
Principal payments on long-term debt			(23,246)	(17,275)
Common stock withheld for minimum statutory taxes, net			(2,134)	(3,678)
Other			(1,742)
Cash provided by (used in) intercompany activity			34,202	16,154
Net cash used in financing activities			7,080	(4,799)
Combined Subsidiary Guarantors [Member]
Operating activities:
Net income	49,919	42,993	93,458	75,376
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Depreciation and amortization	18,611	16,404	36,783	31,955
Deferred income taxes			(5,843)	12,268
Other			1,149	1,181
Change in operating assets and liabilities:
Accounts receivable, net			(23,064)	(13,423)
Other current assets			12,197	(3,564)
Other assets			2,689	1,705
Accounts payable and other accrued liabilities			27,859	3,747
Accrued salaries and benefits			4,487	(6,591)
Other liabilities			3,002	1,625
Net cash provided by continuing operating activities			152,717	104,279
Net cash used in discontinued operating activities			(572)	(829)
Net cash provided by operating activities			152,145	103,450
Investing activities:
Cash paid for capital expenditures			(97,186)	(71,274)
Cash paid for real estate acquisitions			(8,857)	(22,850)
Other			(5,759)	(7,543)
Net cash used in investing activities			(111,802)	(101,667)
Financing activities:
Principal payments on long-term debt			(169)
Other			(1,924)	(2,270)
Cash provided by (used in) intercompany activity			(25,131)	32,629
Net cash used in financing activities			(27,224)	30,359
Net increase in cash and cash equivalents			13,119	32,142
Cash and cash equivalents at beginning of the period			46,860	15,681
Cash and cash equivalents at end of the period	59,979	47,823	59,979	47,823
Combined Non-Guarantors [Member]
Operating activities:
Net income	25,833	18,460	49,892	32,630
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Depreciation and amortization	21,317	18,797	42,918	36,859
Amortization of debt issuance costs			(202)	(208)
Deferred income taxes			427	3,218
Other			(349)	2,685
Change in operating assets and liabilities:
Accounts receivable, net			(3,040)	(8,981)
Other current assets			(2,244)	24,021
Other assets			72	104
Accounts payable and other accrued liabilities			(6,793)	(8,640)
Accrued salaries and benefits			(123)	(2,566)
Other liabilities			(3,795)	3,632
Net cash provided by continuing operating activities			76,763	82,754
Net cash provided by operating activities			76,763	82,754
Investing activities:
Cash paid for capital expenditures			(64,369)	(46,247)
Other			2,422	1,605
Net cash used in investing activities			(61,947)	(44,642)
Financing activities:
Principal payments on long-term debt			(4,345)	(3,397)
Other			(1,506)
Cash provided by (used in) intercompany activity			(9,071)	(48,783)
Net cash used in financing activities			(14,922)	(52,180)
Effect of exchange rate changes on cash			(840)	4,297
Net increase in cash and cash equivalents			(946)	(9,771)
Cash and cash equivalents at beginning of the period			20,430	41,382
Cash and cash equivalents at end of the period	$ 19,484	$ 31,611	$ 19,484	$ 31,611